Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 24, 2026.

Glucose Metabolism and Glucose Transporters in Breast Cancer

Eunah Shin, Ja Seung Koo

Frontiers in Cell and Developmental Biology · 2021 · Review · CC BY

doi:10.3389/fcell.2021.728759 (opens in a new tab)

Abstract

Breast cancer is the most common malignancy in women worldwide and is associated with high mortality rates despite the continuously advancing treatment strategies. Glucose is essential for cancer cell metabolism owing to the Warburg effect. During the process of glucose metabolism, various glycolytic metabolites, such as serine and glycine metabolites, are produced and other metabolic pathways, such as the pentose phosphate pathway (PPP), are associated with the process. Glucose is transported into the cell by glucose transporters, such as GLUT. Breast cancer shows high expressions of glucose metabolism-related enzymes and GLUT, which are also related to breast cancer prognosis. Triple negative breast cancer (TNBC), which is a high-grade breast cancer, is especially dependent on glucose metabolism. Breast cancer also harbors various stromal cells such as cancer-associated fibroblasts and immune cells as tumor microenvironment, and there exists a metabolic interaction between these stromal cells and breast cancer cells as explained by the reverse Warburg effect. Breast cancer is heterogeneous, and, consequently, its metabolic status is also diverse, which is especially affected by the molecular subtype, progression stage, and metastatic site. In this review, we will focus on glucose metabolism and glucose transporters in breast cancer, and we will additionally discuss their potential applications as cancer imaging tracers and treatment targets.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 24, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Breast cancer is the most common malignancy in women worldwide, and ranks top in the cause of death in female cancers worldwide. A total of 2.1 million women were newly diagnosed with breast cancer in 2018, and 627,000 women died of breast cancer. Breast cancer is increasing in underdeveloped and developing countries, and it is decreasing in developed countries since the early 2000s. Breast cancer presents with diverse characteristics. To categorize such diverse features of breast cancer, molecular subtypes have been developed: luminal A, luminal B, HER-2, and basal-like type. Moreover, estrogen receptor (ER), progesterone receptor (PR), and HER-2 are the main targets for targeted therapy in breast cancer, and samples/cases that are negative for these three receptors are defined as triple negative breast cancer (TNBC), which comprises about 15% of breast cancer cases. Each of the molecular subtypes of breast cancer and TNBC shows distinct clinical and molecular features in treatment response. Generally, breast cancer is treated with surgery, chemo-radiotherapy, and targeted therapy for biomarkers. Breast cancer showing hormone receptor expressions is treated with hormonal therapy such as tamoxifen, and breast cancer showing HER-2 amplification is treated with targeted therapy such as trastuzumab. Those that do not have any treatment targets are treated with a non-specific chemotherapy.

One of the fundamental characteristics of cancer cells that differs from normal cells is metabolic reprogramming—producing energy through glycolysis rather than mitochondrial oxidative phosphorylation, which is known as the Warburg effect after the German scientist Otto Warburg who first described it in the 1950s. The Warburg effect was first described in the 1950s by Otto Warburg, a German scientist, who stated that cancer cells secrete high levels of lactate because of an increase in glycolysis. In the process of glycolysis, which is one of the main processes of glucose metabolism, glucose can enter cancer cells by glucose transporters. As a result, various glucose metabolites are produced that are related to diverse metabolic pathways, such as the serine/glycine metabolic pathway and pentose phosphate pathway (PPP). These glucose metabolic pathways and glucose transporters have pivotal roles in cancer metabolism as well as in cancer progression and metastasis, and such metabolic characteristics can be used in imaging diagnosis and targeted therapies. This review will focus on the glucose metabolic pathways, such as glycolysis, serine/glycine pathway, and PPP, in breast cancer and glucose transporters used in glycolysis and their potential implications in clinical practice.

General Aspects of Glucose Metabolism and Related Metabolic Pathways in Cancer

Glucose metabolism consists of glycolysis and PPP, and glycolysis-related metabolic pathways consist of serine and glycine metabolism (Figure 1). A major pathway in the glucose metabolism of cancer cells is aerobic glycolysis, in the process of which glucose is first transported into the cancer cells by glucose transporters and then metabolized to pyruvate by various enzymes. Many enzymes are involved in this process, of which, the key enzymes are hexokinase II (HKII), phosphofructokinase (PFK), and pyruvate kinase (PK). Pyruvates produced in glycolysis are then moved into the mitochondria by mitochondrial pyruvate carriers 1 and 2, where they are turned into acetyl-CoA and oxaloacetate by pyruvate dehydrogenase and pyruvate carboxylase, respectively, to enter the TCA cycle for oxidative phosphorylation (OXPHOS). With one of the intermediate metabolites produced during the process of glycolysis, 3-phosphoglycerate (3PG), starts the serine pathway, in which 3-phosphoglycerate (3PG) is oxidized to 3-phosphohydroxypyruvate (pPYR) by phosphoglycerate dehydrogenase (PHGDH) and pPYR is transaminated to phosphoserine (pSER) by phosphoserine aminotransferase (PSAT). pSER is dephosphorylated to serine by phosphoserine phosphatase. In glycine metabolism, glycine is metabolized to H-protein-S-aminomethyldihydrolipoyllysine by glycine decarboxylase (GLDC), an important component of the glycine cleavage system. This serine metabolism and glycine metabolism are linked by serine hydroxymethyltransferse (SHMT), which causes a reversible conversion of serine and glycine. Lastly, PPP is a metabolic pathway that occurs with glycolysis, playing a pivotal role in cell survival and growth by providing pentose phosphate for nucleic acid synthesis and also nicotinamide adenine dinucleotide phosphate (NADPH) for fatty acid synthesis and cell survival. PPP is comprised of two branches, the oxidative branch and non-oxidative branch. The oxidative branch converts glucose 6-phosphate (G6P) to ribulose-5-phosphate, CO2, and NADPH, and the non-oxidative branch produces glycolytic intermediates, such as fructose 6-phosphate (F6P), glyceraldehyde 3-phosphate (G3P), and sedoheptulose. These glycolytic intermediates are important for amino acid synthesis and produce ribose-5-phosphate (R5P) that is also important for nucleic acid synthesis. Enzymes that are involved in the oxidative branch are 6-phosphogluconate dehydrogenase (6PGD) and glucose 6-phosphate dehydrogenase (G6PD), and those that are involved in the non-oxidative branch are ribulose-5-phosphate epimerase (RPE), ribose 5-phosphate isomerase (RPI), transaldolase (TALDO), and transketolase (TKT).

Cancer cells produce a high level of reactive oxygen species (ROS) compared to normal cells due to the increased activation of various metabolic pathways. Cancer cell metabolism is closely related to ROS homeostasis; they cause ROS detoxifications by using various substrates and metabolic intermediates in metabolic pathways, the most representative of which are glycolysis by the Warburg effect and PPP. Glycolysis by the Warburg effect maintains redox homeostasis by being independent of mitochondrial OXPHOS that produces a large amount of ROS, and PPP by producing ROS-detoxifying molecule, NADPH, by G6PD and 6-Phosphogluconate dehydrogenase (6PGDH).

Molecules involved in the regulation of glucose metabolism in cancer in general are oncogenes such as Ras, Src, and MYC, transcription factors such as hypoxia-inducible factor-1 (HIF-1), signaling pathway such as phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR), and tumor suppressor such as p53. Oncogenes such as Ras, Src, and MYC increase the expression of HIF-1 that increases the expression of various glycolytic enzymes, and HIF-1, MYC, and KRAS increase glucose uptake by inducing GLUT expression. In addition, the PI3K/Akt/mTOR pathway induces glycolytic enzymes and GLUT expression, and p53 regulates glycolysis and GLUT through mTOR and AMP-activated protein kinase (AMPK).

Glucose Transporters in Glycolysis

There are two families of glucose transporters: facilitative sugar transporters (GLUT, gene family name SLC2A) and Na+/glucose co-transporters (SGLT, gene family name solute carrier SLC5A). Additionally found families of glucose transporters are the Sugars Will Eventually be Exported Transporters (SWEET; SLC50) family and the Spinter protein (SLC63) family. SLC50 is a Na (+)/substrate co-transporter involved in the transport of glucose, myoinositol, and anions and located in the plasma membrane. SGLT1 (SLC5A1) and SGLT2 (SLC5A2) are important in glucose uptake with the former expressed mainly in the intestine and the latter in the kidney. GLUT has 14 isoforms that share structural features, such as 12 transmembrane domains, amino terminus, carboxy-terminus, and an N-glycosylation site. GLUTs can be subgrouped into three classes: class I (GLUT1–4 and GLUT14), class II (GLUT5, 7, 9, and 11), and class III (GLUT6, 8, 10, 12, and 13). Class I and class II GLUTs are called odd transporters, whereas class III GLUTs are called even transporters. Except for GLUT13, which is a proton-driven myoinositol transporter, all GLUTs are facilitative transporters. These GLUT isoforms differ in the tissue type in which they are present, their location within the cells, cohesiveness with substrates, and control mechanism. For instance, GLUT1 and GLUT3 are found in the brain, where they function mainly in glucose transport, whereas GLUT3–5 and GLUT10–11 are found in the muscle. Glucose is an important substrate for GLUT, but GLUT can also transport other substrates such as galactose, mannose, glucosamine, dehydroacetic acid, fructose, urate, and myo-inositol.

Glucose Metabolism and Glycolysis-Related Metabolic Pathways in Breast Cancer

Cancer cells harbor a metabolic shift to aerobic glycolysis that plays an important role in tumor growth, progression, and metastasis; therefore, glucose metabolism and glycolysis-related metabolic pathways can have a diverse impact on cancer cells in breast cancer.

Expression of Glycolysis-Related Enzymes and GLUTs in Breast Cancer

Breast cancer shows an increased expression of glycolysis-related enzymes, namely, HKII, 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3 (PFKFB3), and pyruvate kinase M2 (PKM2). In primary breast cancer, HKII is overexpressed in about 79% of tumors, which has been correlated with an increased histologic grade and proliferative activity. The expression of 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3 activates PFK-1, a key enzyme in glycolysis, and is correlated with HER-2 expression and poor prognosis. Additionally, 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3 expression is related to the expression of vascular endothelial growth factor (VEGF)-α in breast cancer, which contributes to angiogenesis and distant metastasis. PFK-2 is a muscle isoform M2 of PK, a key enzyme in glycolysis, and its expression is correlated with a poor prognosis in breast cancer. Lactates produced by glycolysis are transported in and out of cells by monocarboxylate transporter (MCT). MCT1 overexpression in breast cancer is correlated with ER negativity, PR negativity, high Ki-67 labeling index, basal-like type, high grade, high stage, increased recurrence, and poor prognosis. As for MCT4, tumoral MCT4 expression and stromal MCT4 expression are associated with poor prognosis.

Breast cancer has been reported to have an increased expression of GLUT1–6 and 12 (Table 1; ), and the most important glucose transporter for glucose uptake in breast cancer is GLUT1. Glucose uptake by GLUT1 is important in the carcinomatous transformation and carcinogenesis of breast cancer, and it plays an important role in the early phase of breast cancer development. GLUT1 overexpression in breast cancer is correlated with high histologic grade, high proliferative activity, poor differentiation, and poor prognosis. GLUT4 is an insulin-stimulated glucose transporter, and glucose uptake is dependent on insulin stimulation in cancer cell lines. It has also been reported that hyperinsulinemia increases the risk of breast cancer irrespective of the body mass index (BMI), and so it can be postulated that insulin is associated with breast cancer. Cross-talks between signaling pathways regulated by 17 beta-estradiol (E2) and insulin-like growth factor (IGF), strong mitogen for cancer cells, and actions through ER-signaling are some possible mechanisms associated with the insulin effect on breast cancer.

Overexpression of glycolysis-related enzymes and GLUTs in breast cancer is due to the activation of the signaling pathways controlling the enzyme expression in breast cancer (Figure 2). The main molecular pathways involved in the control of aerobic glycolysis are the PI3K/AKT, AMP-activated protein kinase (AMPK), mitogen-activated protein kinase, Wnt, and mTOR pathways. Among these, the PI3K/AKT, AMPK, and mTOR pathways are activated in breast cancer. PI3K/AKT activates phosphofructokinase-2 (PFK-2) by phosphorylation. PI3K/AKT pathway activation leads to GLUT1 overexpression, which is then translocated from the cytoplasm to the plasma membrane. AKT is activated by E2, thus increasing the glucose uptake in MCF-7 breast cancer cell line through translocation of GLUT4 to the plasma membrane. PIK3CA and AKT1 gene mutations are common in breast cancer, and PIK3CA mutation is usually found in ER-positive and HER-2 positive breast cancer. AMPK translocates GLUT4 to the cytoplasmic membrane by activating PFK-2 and increases GLUT1 expression. AMPK is highly expressed in TNBC and known to be associated with poor prognosis. mTOR is a downstream effector of AKT, comprising mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). mTORC1 promotes the transition from OXPHOS to glycolysis and increases the expression of HIF-1α, which in turn increases the expression of glycolysis-related enzymes such as PFK. mTORC2 promotes glycolysis by activating AKT and GLUT1-related glucose uptake. mTOR is activated in breast cancer through HER-2 overexpression, PI3K pathway alteration, and mTOR mutation. Second, the increased expression of glycolysis-related enzymes in breast cancer is because of the activation of transcription factors (Figure 2). The transcription factors associated with glycolysis are c-myc, p53, and HIF-1. c-myc is responsible for increasing the gene expression of glycolysis-related genes and, consequently, glycolysis-related enzymes, such as GLUT, HK, and PFK. Moreover, estrogen is responsible for the increased expression of c-myc, and about 80% of breast cancers are ER-positive. p53 is a well-known tumor suppressor, gene mutations of which are found in most cancers including breast cancer. p53 mutation is found in about 20%–30% of breast cancers and more often in ER-negative breast cancer. p53 suppresses phosphoglycerate mutase (PGM), GLUT1, GLUT3, and GLUT4 expression; hence, p53 mutation leads to an increased glycolysis in breast cancer. Lastly, the transcription factor HIF-1α, which is activated by hypoxia, is an important regulator in glycolysis and increases the expression of glycolysis-related molecules, such as HKII, PFK-1, lactate dehydrogenase (LDH) A, GLUT-1, and GLUT-3. HIF-1α promotes the metabolic shift to glycolysis by suppressing the mitochondrial function through the activation of pyruvate dehydrogenase kinase 1 (PKD1) and MAX interactor 1 (MXI1). HIF-1α overexpression has been reported in breast cancer, and it is attributed to the increased expression of glycolysis-related proteins in breast cancer because HIF-1α overexpression is related to HER-2 positivity and TNBC.

Breast cancer is susceptible to sex hormones such as estrogen, which may have an effect on the regulation of glucose metabolism. E2 and ERα stimulation activates the MAPK pathway, regulates expression of GLUT4, and increases glucose uptake. Furthermore, E2 activates the PI3K pathway that is involved in glucose metabolism in breast cancer cells, and suppresses phosphatase and tensin homolog (PTEN), a phosphatidylinositol-3 kinase inhibitory protein.

Expression of Glycolysis-Related Enzymes and GLUTs in TNBC

Triple negative breast cancer is defined as breast cancer that is negative for ER, PR, and HER-2 and accounts for about 15% of breast cancer cases. Basal-like breast cancer (BLBC) is defined as those that have high expressions of basal genes in gene expression studies such as DNA microarray. Therefore, TNBC and BLBC are not the same in the strict sense of definitions, although they can overlap in many instances. TNBC is a heterogeneous group, and many researches have focused on the subgrouping of TNBC. have grouped TNBC further into basal-like1, basal-like2, mesenchymal, and luminal androgen receptor, and have grouped TNBC further into basal-like immune-activated, basal-like immune suppressed, mesenchymal, and luminal androgen receptor. The general characteristics of TNBC include the histological characteristics of high grade, high proposition index, and tumor necrosis, and clinical characteristics of higher rate of metastasis and poor prognosis. With these histological and clinical features, TNBC can be postulated to be of high metabolic status. One of the important metabolic features of TNBC is high glucose uptake, and GLUT1 overexpression is seen in TNBC. High expression of glycolysis-related enzymes, such as HK2, PKM2, and LDH, and that of lactate transporters MCT1 and MCT4 have also been reported in TNBC. The high expression of glycolysis-related proteins in TNBC is owing to the fact that the glycolysis regulatory factors, such as HIF-1, c-myc, and EGF signaling, are promoted in TNBC. Therefore, TNBC cells are much more dependent on glucose metabolism than non-TNBC cells (MCF-7), and GLUT1 inhibition shows a more anti-proliferative effect for TNBC cells than non-TNBC cells (MCF-7).

Non-glycolysis Glucose Metabolism Pathway in Breast Cancer

In glucose metabolism, non-glycolysis metabolic pathways, such as the serine/glycine metabolic pathway and PPP, play important roles in breast cancer. The expression of serine/glycine metabolic pathway-related proteins in breast cancer differs depending on the breast cancer molecular subtype. Serine metabolic pathway-related proteins were highly expressed in TNBC, and glycine metabolic pathway-related proteins were highly expressed in HER-2 type breast cancer. The basal-like type also showed a higher expression of serine/glycine metabolic pathway-related proteins among the TNBC subtypes. Analysis using the cBioPortal TCGA Pan-Cancer Atlas shows PHGDH amplification in approximately 2.2% of breast cancers. PHGDH expression is observed frequently in ER-negative breast cancer, and increased PHGDH expression in breast cancer is associated with poor prognosis. Similarly, phosphoserine aminotransferase 1 (PSAT1) is more frequently expressed in ER-negative breast cancer and is associated with poor prognosis. Serine hydroxymethyltransferase 2 expression level is associated with the histologic grade of breast cancer.

High expression of PPP-related enzymes, such as 6PGD and TKT, is reported in breast cancer. G6PD, one of the PPP-related enzymes, is associated with the molecular subtype of breast cancer, and G6PD overexpression is associated with poor prognosis of breast cancer. 6PGDH expression is high in TNBC, and the expression of G6PDH and 6PGL are high in HER-2 type. The expression of G6PDH is also the highest in brain metastasis among metastatic breast cancers. The expression of TKT is associated with tumor size and high TKT expression is associated with poor prognosis in a mouse model of breast cancer. Increased PPP flux by G6PD and HK2 enhancement induces tamoxifen resistance in breast cancer. An increase in HK2 transcription by the yes-associated protein (YAP) axis also promotes the migration of breast cancer cells.

Glucose Metabolism in the Tumor Microenvironment of Breast Cancer

Breast cancer is one of those tumors that harbors tumor stroma, the main cell components of which include cancer-associated fibroblasts (CAFs), cancer-associated adipocytes (CAAs), and immune cells. These stromal cells affect the development, progression, and metastasis of breast cancer through various interactions with breast cancer cells. Thus, metabolic interactions are present between breast cancer cells and stromal cells (Figure 3), and glucose metabolism in tumor stromal cells is suggested in the reverse Warburg effect. According to the reverse Warburg effect, aerobic glycolysis occurs in CAFs that are present in the breast cancer stroma. In brief, the reverse Warburg theory describes the glycolysis that occurs in CAFs by ROS, HIF1A, and nuclear factor-κB (NF-κB), resulting in lactate being released from CAFs by MCT4, which is then transported into the tumor cells by MCT1 in breast cancer, creating energy by mitochondrial OXPHOS. Lactate produced by CAFs is transported into the tumor cells as potent nutrients for the TCA cycle, and this lactate can be an important source of energy for cancer cells because lactate is the primary source of carbon for the TCA cycle among circulating metabolites. In co-cultural studies of breast cancer cell lines and fibroblasts and studies of human breast cancer tissue, MCT4 was expressed in CAFs, whereas MCT1 was expressed in tumor cells. In a co-cultural study of MCF7 breast cancer cells and normal fibroblasts, culture of MCF7 breast cancer cells alone or fibroblasts alone did not exhibit MCT4 expression, whereas co-culture of MCF7 breast cancer cells and fibroblasts showed MCT4 expression in CAFs. The co-culture with fibroblasts showed MCT1 upregulation in MCF7 breast cancer cells. Breast CAFs showed higher expressions of GLUT1 and PDK1 than normal fibroblasts, and the co-cultural study of breast cancer cells and fibroblasts showed an increase in glycolysis and glucose transporter-related genes in CAFs. The reverse Warburg effect is not only observed between cancer cells and CAFs but also between hypoxic and oxygenated cancer cells.

One type of immune cells in the tumor stroma is tumor-associated macrophages (TAMs) that inhibit antitumor immunity in breast cancer, resulting in tumor progression. In general, TAMs exhibit properties of M2 macrophages, and TAMs in hypoxic tumor regions express HIF-1, which controls the expression of glycolysis-related genes, including GLUT1, HK2, PFFB3, and PGK1. Therefore, TAMs in hypoxic tumor environments may utilize glycolysis. In addition, lactate generated in the glycolysis process is an important metabolite, which activates M2 macrophages. In a co-culture study of breast cancer cells and macrophages, G protein-coupled receptor 132 (Gpr132) senses lactate in the tumor environment to transform macrophages into M2-like phenotypes to promote cancer cell adherence, migration, and invasion. In addition, HIF-1α-stabilizing long non-coding RNA (HISLA) is transferred from TAMs to breast cancer cells via extracurricular vessel transmission, which increases glycolysis in breast cancer cells.

Impact of Glucose Metabolism and Glucose Transporters on Breast Cancer Biology and the Response to Treatment

First, the proliferation of tumor cells requires a lot of energy and a variety of materials are needed to create new tumor cells, which is also true for breast cancer cells. Therefore, glucose metabolism and glucose transporters, which provide energy sources for breast cancer, and PPP, which provides the materials needed for the synthesis of nucleotides, lipids, and non-essential amino acids, play important roles in breast cancer proliferation. Second, glucose metabolism affects the maintenance of epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) phenotype in breast cancer. Increased glycolysis and PPP by epigenetic silencing of fructose-1,6-biphosphatase can increase NADPH and reduce ROS levels, which enhance EMT and CSC phenotype in basal-like breast cancer. In a breast cancer cell line study, high glucose levels increased glycolytic enzyme, motor protein, and NF-κB levels and glucose uptake, and reduced actin, resulting in EMT phenotype activation. In addition, HIF-1 activation by hypoxia maintains ROS homeostasis through the glycolytic pathway and serine synthesis pathway, which is important for breast CSC induction. Moreover, glucose metabolism is associated with treatment resistance in breast cancer, where induced glycolysis is observed by AKT/mTOR/HIF-1α axis activation in tamoxifen resistant breast cancer cells, and when HKII is inhibited, tamoxifen sensitivity is recovered. Increased glycolysis is observed in trastuzumab resistant breast cancer cells, and glycolytic inhibition reduces trastuzumab resistance. The expression of PFK-2 is linked to the responsiveness of anticancer drugs such as epirubicin and 5-fluorouacil in breast cancer cells. Chemoresistant TNBC cells exhibit increased glycolysis and lactate permutation, and PHGDH expression correlates with the responsiveness of chemotherapy in TNBC cells. GLUT is associated with breast cancer metastasis; a proteomic analysis of MDA-MB-231 (metastatic breast cancer cell line) and MCF-10A (normal breast epithelial cell line) showed that one of the three strongest breast cancer-related proteins was GLUT1. The GLUT expression showed a difference according to the metastatic sites, and the expression of GLUT1 was the highest in brain metastasis. Additionally, GLUT12 plays an important role in tumor growth and metastasis through aerobic glycolysis in TNBC.

Clinical Application of Glucose Transporters and Glucose Metabolism in Breast Cancer

As we have seen earlier, glucose transporter expression is high in breast cancer, and glucose metabolism is carried through the glycolytic, serine/glycine, and PPPs that play important roles in tumor growth and progression. Therefore, they may have a variety of clinical applications, especially in imaging diagnosis and targeted therapy.

Imaging Diagnosis

Positron emission tomography (PET) using 18F-fluorodeoxy glucose (FDG), a radioactive analog of glucose, is the representative functional imaging technique based on the principle that tumor cells uptake large amounts of glucose by GLUT via the Warburg effect. These PETs are used for tumor staging and treatment response monitoring. These FDG-PET/CTs are also useful for diagnosis, staging, and treatment evaluation in breast cancer. In addition to FDG-PET/CT, functional imaging based on glucose metabolism can be performed using magnetic resistance spectroscopy (MRS). Multiple metabolites can be simultaneously identified in tumor tissues using MRS, which can analyze labeling patterns using stable isotopic traces, and glucose metabolites can be analyzed using 13C-MRS and [13C]-labeled glucose to image the glycolysis status. MRS can perform effective metabolic monitoring in breast cancer. Breast cancer with different 13C-MRS expression patterns show a different glucose metabolism. A high-resolution magic angle spinning MRS analysis of metabolites in breast cancer, such as β-glucose, lactate, and glycine, shows good prognosis with reduced concentrations of glycine. The concentration of β-glucose shows a negative correlation with proliferation index (MIB-1), indicating that MR metabolite analysis is valuable in breast cancer prognostication.

Therapeutic Target of Glucose Metabolism and Glucose Transporters

The expression of glucose transporters and glucose metabolic enzymes in breast cancer is high; thus, their inhibition can serve as an effective treatment strategy against breast cancer (Figure 4). Various preclinical and clinical studies have been conducted to investigate this implication.

GLUT1 Inhibitors

GLUT1 inhibitors—WZB117 and SFT-31—inhibit cell proliferation and promote apoptosis in breast cancer cell lines. WZB117 increases the effectiveness of radiation and anticancer drugs in breast cancer cell lines. BAY-876, a selective GLUT1 inhibitor, decreases glucose uptake in TNBC cell lines and 2-deoxy-D-glucose (2-DG), a synthetic non-metabolizable glucose analog, competes with glucose for binding GLUT, which reduces glucose uptake in the MDA-MB-231 TNBC cell line. As for 2-DG, there are two different phenomena resulting from the suppression of glycolysis: first, glucose can be deviated to PPP because 2-DG is not metabolized any further after phosphorylation into 2-deoxy-D-glucose-6-phosphate (2-DG-6-P) by HKII; and second, 2-DG induces autophagy due to endoplasmic reticulum (ER) stress. Suppression of glycolysis leads to a decreased ATP, by which N-linked glycosylation is suppressed and AMPK is activated. AMPK activation and N-linked glycosylation lead to ER stress. Autophagy promotes tumor growth in the early stage of cancer, maintains tumor survival, and increases metastasis in the advanced stage. Anti-GLUT1 monoclonal antibody decreases glucose uptake in the MDA-MB-231 TNBC cell line, and decreases cancer cell proliferation and promotes apoptosis in MCF-1 and T47D breast cancer cell lines. Polyphenols, a huge family of natural compounds found in plants or food, is one category of the GLUT1 inhibitors that shows an anti-tumoral effect against various cancers including breast cancer. The anti-tumoral mechanism of polyphenols against breast cancer includes increased apoptosis, cell cycle arrest, enhanced autophagy, decreased angiogenesis, anti-inflammatory effect, blockade for estrogen, aromatase modulation, altered redox balance, and inhibition of the HER-2 pathway. Polyphenols inhibiting GLUT1 in breast cancer are as follows: Resveratol suppresses glucose uptake in T-47D cell line by reducing GLUT1 protein level, and hesperetin suppresses glucose uptake by decreasing GLUT 1 mRNA and protein levels. Quercetin decreases the glucose uptake in MCF-7 and MDA-MB-231 by reducing GLUT1 protein level, as does glabridin in MDA-MB-231. Epigallocatechin-3-gallate (EGCG) decreases the glucose and lactate levels in cancer cells by reducing GLUT1 mRNA levels in 4T1 cell line, and cantharidin suppresses metastasis by inhibiting glucose uptake and lactate production through decreasing GLUT1 protein level in MCF-7 and MDA-MB-231. Kudingcha, one of the Ligustrum robustum species, inhibit cancer proliferation through decreasing GLUT1 protein level in MDA-MB-231 and HCC1806. Vitamin D3 decreases glucose uptake by decreasing GLUT1 mRNA and protein levels in MCF-7 and MDA-MB-231.

Glucose Metabolic Enzyme Inhibitors

First, 3-bromopyruvate (3-BrPA), an inhibitor of hexokinase, causes apoptosis in MDA-MB-231 breast cancer cell line and increases the response to daunorubicin and tamoxifen in breast cancer. Methyl jasmonate, another hexokinase inhibitor, caused a decrease in tumor volume in mice bearing 4T1 breast cancer cell line. Resveratrol, an inhibitor of PFK, decreases the cell viability and glucose consumption in MCF-7 breast cancer cell line. Cyclosporin A, an immunosuppressive agent, inhibits the expression and activity of PKM2 in breast cancer cell lines (MCF-7, MDA-MB-435, and MDA-MB-231) and causes tumor cell death by reducing cell viability. Cyclosporin A also maintains mitochondrial function by suppressing mitochondrial permeability transition pore. When oxamate, an LDH inhibitor, is administered in conjunction with doxorubicin and metformin, it causes a rapid tumor growth inhibition in the xenograft model using human MDA-MB-231 TNBC cell line. When paclitaxel and oxamate are administered together, they induce an effective killing of paclitaxel-resident TNBC cells. Gossypol, a lipid soluble polyphenolic compound, exhibits antitumor effects by inhibiting glycolysis through LDH isoenzyme type 5 inhibition. Gossypol causes anti-proliferative activity and apoptosis in breast cancer cells, and when R--gossypol (AT-101) is administered in conjunction with trastuzumab in HER-2 positive breast cancer cell line, it causes synergistic cytotoxicity and apoptosis. Galloflavin, an LDHA inhibitor, induces cell death in MDA-MB-231 cell lines and acquired tamoxifen resistance MCF-7 breast cancer cell lines.

Serine and glycine pathway inhibitors can be used for the management of tumors that use serine and glycine metabolism and for treatment of tumors showing recurrence and treatment resistance. PHGDH inhibitors—NCT-503 and CBR-5884—are both allosteric PHGDH inhibitors; NCT-503 binds to the near substrate-binding pockets; and CBR-5884 hinders PHGD holigomerization. NCT-503 inhibits tumor growth in PHGDH-amplified breast cancer xenografts, and CBR-5884 inhibits tumor cell proliferation in high PHGDH-expressing breast cancer cell lines (MDA-MB-468, MDA-MB-436, HCC70, and Hs578T). PKUMDL-WQ-2101 and PKUMDL-WQ-2201, which are allosteric PHGDH inhibitors, show an antitumor activity in PHGDH-amplified breast cancer cell lines (MDA-MB-468 and HCC70). An NAD-competitive PHGDH inhibitor, 15 fragments, reduces cell proliferation in PHGDH-amplified breast cancer cell line (MDA-MB-468). Sertraline, an antidepressant, is a selective serotonin reuptake inhibitor (SSRI) class, but it also works as a competitive dual SHMT1/2 inhibitor, reducing the cell growth in serine/glycine synthesis-addicted breast cancer cell line (MDA-MB-468) and decreasing the tumor growth in a mouse xenograft study.

G6PD, one of the important enzymes in PPP, has a potent non-competitive inhibitor, dehydroepiandrosterone (DHEA), which is an adrenal cortical steroid. DHEA inhibits the growth and migration of breast cancer cell lines (MCF-7, MDA-MB-231, and Hs578T). DHEA can bind estrogen or androgen receptors because it is metabolized to estrogen or androgen, however, the suppression of MCT-7 cell line growth by DHEA is reported to be independent of estrogen or androgen receptors. 6-aminonicotinamide, a G6PD inhibitor, can decrease mammosphere formation and aldehyde dehydrogenase (ALDH) activity when given with DHEA in breast cancer stem-like cells that show high PPP activity. CB83, another G6PD inhibitor, can inhibit growth of MCF10-AT1 breast cancer cell line. Oxythiamine, an inhibitor of TKT, also increases the response of breast cancer cells to doxorubicin or docetaxel.

Conclusion

Because of the high expressions of GLUT-1 and the enzymes involved in glucose metabolism, tumor cells in breast cancer, as in other tumors, are provided with energy through glucose metabolism. There are several characteristic factors to consider in the glucose metabolism of breast cancer. Because breast cancer is heterogeneous, inter- and intratumoral heterogeneity is also seen in glucose metabolism. First, glucose metabolic activity is different among the molecular subtypes, especially in TNBC, which shows an increased glycolytic phenotype. According to the traditional Warburg theory, tumors showing aerobic glycolysis are suggested to exhibit a decreased mitochondrial OXPHOS; however, TNBC with a high metabolic activity shows both enhanced glycolysis and sustained mitochondrial OXPHOS. Luminal type breast cancer rely more on OXPHOS than glycolysis compared to TNBC. It also presents metabolic switches between glycolysis and OXPHOS during cancer progression. Therefore, metabolic intratumoral heterogeneity is exhibited in breast cancer, showing different glycolytic activities depending on the tumor cell type. Second, there is a metabolic interaction between tumor cells and the surrounding stromal cells in breast cancer. Breast cancer is a typical tumor that contains various stromal cells, the main components of which are CAFs, CAAs, and immune cells. Metabolic interactions exist between breast cancer cells and stromal cells; especially according to the reverse Warburg theory, lactates produced by glycolysis in CAFs enter tumor cells and produce energy through OXPHOS. Among the immune cells, B-cells and NK cells use glycolysis, and tumor-associated neutrophils use glycolysis and PPP, allowing a metabolic competition with the tumor cells. Third, unlike in other tumors, CAAs are stromal cells that are specifically present in breast cancer, and previous studies suggest that β-oxidation in tumor cells is primarily studied through the lipid transfer between CAAs and tumor cells. As the glucose metabolic interaction between CAAs and tumor cells is rarely studied in breast cancer, it requires further study. Metabolic interactions between tumor cells and stromal cells in these breast cancer cases are also reported to be affected by cancer phenotypes, which may require further research on the metabolic cross-talk between the cancer cells and stromal cells according to the molecular subtype of breast cancer. Fourth, breast cancer shows differential metabolic features depending on the stage and metastatic site. In order for the tumor to progress into distant metastasis, multiple and complex processes, such as intravasation, survival in blood stream, and extravasation, must be accomplished during this process, and the hurdles, such as anchorage independent survival and tumor cell proliferation in foreign microenvironment, should be overcome. One way to overcome this challenge is metabolic reprogramming. Breast cancer shows metabolic differences between the primary and metastatic tumors, and breast cancer does not rely on a single metabolic pathway, but uses multiple metabolic pathways. Highly metastatic 4T1 cells show increased glycolysis and OXPHOS compared to non-metastatic 67NR breast cancer cells. The most common metastatic sites are the brain, bone, lung, and liver, which exhibit differential metabolic features owing to different microenvironments. Liver metastatic breast cancer demonstrates increased glycolytic pathways compared to bone and lung metastatic breast cancer, whereas brain metastatic breast cancer shows increased glycolysis and PPP compared to bone metastatic breast cancer. As a result of the above characteristics of glucose metabolism in breast cancer, further studies are needed to consider tumor imaging using glucose metabolism and glucose metabolic markers as treatment targets. In addition, because glucose metabolism is associated with resistance to anticancer drugs or targeted treatments in breast cancer, glucose metabolic inhibitors can also be considered for a combined therapy with conventional treatments.

Author Contributions

ES and JK: writing—original draft, investigation, and writing—review and editing. Both authors contributed to the article and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References 255

  1. 1.

    Abdel-Wahab A. F. Mahmoud W. Al-Harizy R. M. (2019 ). Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharmacol. Res. 150:104511.

    Not in our library10.1016/j.phrs.2019.104511 (opens in a new tab)

  2. 2.

    Ahmad I. M. Aykin-Burns N. Sim J. E. Walsh S. A. Higashikubo R. Buettner G. R. (2005 ). Mitochondrial O2∗- and H2O2 mediate glucose deprivation-induced stress in human cancer cells. J. Biol. Chem. 280 4254–4263.

    Not in our library10.1074/jbc.m411662200 (opens in a new tab)

  3. 3.

    Alò P. L. Visca P. Botti C. Galati G. M. Sebastiani V. Andreano T. (2001 ). Immunohistochemical expression of human erythrocyte glucose transporter and fatty acid synthase in infiltrating breast carcinomas and adjacent typical/atypical hyperplastic or normal breast tissue. Am. J. Clin. Pathol. 116 129–134.

    Not in our library10.1309/5y2l-cdck-yb55-kdk6 (opens in a new tab)

  4. 4.

    Amaral I. Silva C. Correia-Branco A. Martel F. (2018 ). Effect of metformin on estrogen and progesterone receptor-positive (MCF-7) and triple-negative (MDA-MB-231) breast cancer cells. Biomed. Pharmacother. 102 94–101.

    Not in our library10.1016/j.biopha.2018.03.008 (opens in a new tab)

  5. 5.

    Andrzejewski S. Klimcakova E. Johnson R. M. Tabariès S. Annis M. G. McGuirk S. (2017 ). PGC-1α Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs. Cell Metab. 26 778–787.e5.

    Not in our library10.1016/j.cmet.2017.09.006 (opens in a new tab)

  6. 6.

    Attia Y. M. El-Abhar H. S. Al Marzabani M. M. Shouman S. A. (2015 ). Targeting glycolysis by 3-bromopyruvate improves tamoxifen cytotoxicity of breast cancer cell lines. BMC Cancer 15:838.

    Not in our library10.1186/s12885-015-1850-4 (opens in a new tab)

  7. 7.

    Avanzato D. Pupo E. Ducano N. Isella C. Bertalot G. Luise C. (2018 ). High USP6NL Levels in Breast Cancer Sustain Chronic AKT Phosphorylation and GLUT1 Stability Fueling Aerobic Glycolysis. Cancer Res. 78 3432–3444.

    Not in our library10.1158/0008-5472.can-17-3018 (opens in a new tab)

  8. 8.

    Aykin-Burns N. Ahmad I. M. Zhu Y. Oberley L. W. Spitz D. R. (2009 ). Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation. Biochem. J. 418 29–37.

    Not in our library10.1042/bj20081258 (opens in a new tab)

  9. 9.

    Baenke F. Dubuis S. Brault C. Weigelt B. Dankworth B. Griffiths B. (2015 ). Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survival. J. Pathol. 237 152–165.

    Not in our library10.1002/path.4562 (opens in a new tab)

  10. 10.

    Baretić D. Williams R. L. (2014 ). The structural basis for mTOR function. Semin. Cell Dev. Biol. 36 91–101.

    Not in our library10.1016/j.semcdb.2014.09.024 (opens in a new tab)

  11. 11.

    Barnes K. Ingram J. C. Porras O. H. Barros L. F. Hudson E. R. Fryer L. G. (2002 ). Activation of GLUT1 by metabolic and osmotic stress: potential involvement of AMP-activated protein kinase (AMPK). J. Cell Sci. 115 2433–2442.

    Not in our library10.1242/jcs.115.11.2433 (opens in a new tab)

  12. 12.

    Barron C. C. Bilan P. J. Tsakiridis T. Tsiani E. (2016 ). Facilitative glucose transporters: implications for cancer detection, prognosis and treatment. Metabolism 65 124–139.

    Not in our library10.1016/j.metabol.2015.10.007 (opens in a new tab)

  13. 13.

    Barros R. P. Machado U. F. Warner M. Gustafsson J. A. (2006 ). Muscle GLUT4 regulation by estrogen receptors ERbeta and ERalpha. Proc. Natl. Acad. Sci. U. S. A. 103 1605–1608.

    Not in our library10.1073/pnas.0510391103 (opens in a new tab)

  14. 14.

    Barros R. P. Morani A. Moriscot A. Machado U. F. (2008 ). Insulin resistance of pregnancy involves estrogen-induced repression of muscle GLUT4. Mol. Cell Endocrinol. 295 24–31.

    Not in our library10.1016/j.mce.2008.07.008 (opens in a new tab)

  15. 15.

    Beckwith H. Yee D. (2014 ). Insulin-like growth factors, insulin, and growth hormone signaling in breast cancer: implications for targeted therapy. Endocr. Pract. 20 1214–1221.

    Not in our library10.4158/ep14208.ra (opens in a new tab)

  16. 16.
    Distinct Akt phosphorylation states are required for insulin regulated Glut4 and Glut1-mediated glucose uptake · 2017
    No notice
  17. 17.

    Benesch C. Schneider C. Voelker H. U. Kapp M. Caffier H. Krockenberger M. (2010 ). The clinicopathological and prognostic relevance of pyruvate kinase M2 and pAkt expression in breast cancer. Anticancer Res. 30 1689–1694.

    Not in our library

  18. 18.

    Benito A. Polat I. H. Noé V. Ciudad C. J. Marin S. Cascante M. (2017 ). Glucose-6-phosphate dehydrogenase and transketolase modulate breast cancer cell metabolic reprogramming and correlate with poor patient outcome. Oncotarget 8 106693–106706.

    Not in our library10.18632/oncotarget.21601 (opens in a new tab)

  19. 19.

    Bilan P. J. Mitsumoto Y. Maher F. Simpson I. A. Klip A. (1992 ). Detection of the GLUT3 facilitative glucose transporter in rat L6 muscle cells: regulation by cellular differentiation, insulin and insulin-like growth factor-I. Biochem. Biophys. Res. Commun. 186 1129–1137.

    Not in our library10.1016/0006-291x(92)90864-h (opens in a new tab)

  20. 20.

    Binder C. Binder L. Marx D. Schauer A. Hiddemann W. (1997 ). Deregulated simultaneous expression of multiple glucose transporter isoforms in malignant cells and tissues. Anticancer Res. 17 4299–4304.

    Not in our library

  21. 21.

    Bohndiek S. E. Brindle K. M. (2010 ). Imaging and ‘omic’ methods for the molecular diagnosis of cancer. Expert. Rev. Mol. Diagn. 10 417–434.

    Not in our library10.1586/erm.10.20 (opens in a new tab)

  22. 22.

    Borri F. Granaglia A. (2020 ). Pathology of triple negative breast cancer. Semin. Cancer Biol. 72 136–145.

    Not in our library10.1016/j.semcancer.2020.06.005 (opens in a new tab)

  23. 23.

    Brauer H. A. Makowski L. Hoadley K. A. Casbas-Hernandez P. Lang L. J. Romàn-Pèrez E. (2013 ). Impact of tumor microenvironment and epithelial phenotypes on metabolism in breast cancer. Clin. Cancer Res. 19 571–585.

    Not in our library10.1158/1078-0432.ccr-12-2123 (opens in a new tab)

  24. 24.

    Bray F. Ferlay J. Soerjomataram I. Siegel R. L. Torre L. A. Jemal A. (2018 ). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68 394–424.

    Not in our library10.3322/caac.21492 (opens in a new tab)

  25. 25.

    Bray F. McCarron P. Parkin D. M. (2004 ). The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 6 229–239.

    Not in our library10.1186/bcr932 (opens in a new tab)

  26. 26.

    Brown R. S. Goodman T. M. Zasadny K. R. Greenson J. K. Wahl R. L. (2002 ). Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl. Med. Biol. 29 443–453.

    Not in our library10.1016/s0969-8051(02)00288-3 (opens in a new tab)

  27. 27.

    Brown R. S. Wahl R. L. (1993 ). Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 72 2979–2985.

    Not in our library10.1002/1097-0142(19931115)72:10<2979::aid-cncr2820721020<3.0.co;2-x (opens in a new tab)

  28. 28.

    Bruning P. F. Bonfrèr J. M. van Noord P. A. Hart A. A. de Jong-Bakker M. Nooijen W. J. (1992 ). Insulin resistance and breast-cancer risk. Int. J. Cancer 52 511–516.

    Not in our library10.1002/ijc.2910520402 (opens in a new tab)

  29. 29.

    Bulut G. Atmaca H. Karaca B. (2020 ). Trastuzumab in combination with AT-101 induces cytotoxicity and apoptosis in Her2 positive breast cancer cells. Future Oncol. 16 4485–4495.

    Not in our library10.2217/fon-2019-0521 (opens in a new tab)

  30. 30.

    Burke B. Giannoudis A. Corke K. P. Gill D. Wells M. Ziegler-Heitbrock L. (2003 ). Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am. J. Pathol. 163 1233–1243.

    Not in our library10.1016/s0002-9440(10)63483-9 (opens in a new tab)

  31. 31.

    Burstein M. D. Tsimelzon A. Poage G. M. Covington K. R. Contreras A. Fuqua S. A. (2015 ). Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin. Cancer Res. 21 1688–1698.

    Not in our library10.1158/1078-0432.ccr-14-0432 (opens in a new tab)

  32. 32.

    Butt A. J. Sergio C. M. Inman C. K. Anderson L. R. McNeil C. M. Russell A. J. (2008 ). The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome. Breast Cancer Res. 10:R28.

    Not in our library10.1186/bcr1985 (opens in a new tab)

  33. 33.
    Chibby suppresses aerobic glycolysis and proliferation of nasopharyngeal carcinoma via the Wnt/β-catenin-Lin28/let7-PDK1 cascade · 2018
    Not checked
  34. 34.

    Caresia Aroztegui A. P. García Vicente A. M. Alvarez Ruiz S. Delgado Bolton R. C. Orcajo Rincon J. Garcia Garzon J. R. (2017 ). 18F-FDG PET/CT in breast cancer: evidence-based recommendations in initial staging. Tumour Biol. 39:1010428317728285.

    Not in our library10.1177/1010428317728285 (opens in a new tab)

  35. 35.

    Carey L. Winer E. Viale G. Cameron D. Gianni L. (2010 ). Triple-negative breast cancer: disease entity or title of convenience? Nat. Rev. Clin. Oncol. 7 683–692.

    Not in our library10.1038/nrclinonc.2010.154 (opens in a new tab)

  36. 36.

    Castaneda C. A. Cortes-Funes H. Gomez H. L. Ciruelos E. M. (2010 ). The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. Cancer Metastasis Rev. 29 751–759.

    Not in our library10.1007/s10555-010-9261-0 (opens in a new tab)

  37. 37.

    Cha Y. J. Jung W. H. Koo J. S. (2017 ). Differential Site-Based Expression of Pentose Phosphate Pathway-Related Proteins among Breast Cancer Metastases. Dis. Markers 2017:7062517.

    Not in our library10.1155/2017/7062517 (opens in a new tab)

  38. 38.

    Chen E. I. Hewel J. Krueger J. S. Tiraby C. Weber M. R. Kralli A. (2007 ). Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res. 67 1472–1486.

    Not in our library10.1158/0008-5472.can-06-3137 (opens in a new tab)

  39. 39.

    Chen F. Chen J. Yang L. Liu J. Zhang X. Zhang Y. (2019 ). Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nat. Cell Biol. 21 498–510.

    Not in our library10.1038/s41556-019-0299-0 (opens in a new tab)

  40. 40.

    Chen P. Zuo H. Xiong H. Kolar M. J. Chu Q. Saghatelian A. (2017 ). Gpr132 sensing of lactate mediates tumor-macrophage interplay to promote breast cancer metastasis. Proc. Natl. Acad. Sci. U. S. A. 114 580–585.

    Not in our library10.1073/pnas.1614035114 (opens in a new tab)

  41. 41.

    Chen Q. Meng Y. Q. Xu X. F. Gu J. (2017 ). Blockade of GLUT1 by WZB117 resensitizes breast cancer cells to adriamycin. Anticancer Drugs 28 880–887.

    Not in our library10.1097/cad.0000000000000529 (opens in a new tab)

  42. 42.

    Chen Y. Wei L. Zhang X. Liu X. Chen Y. Zhang S. (2018 ). 3-Bromopyruvate sensitizes human breast cancer cells to TRAIL-induced apoptosis via the phosphorylated AMPK-mediated upregulation of DR5. Oncol. Rep. 40 2435–2444.

    Not in our library10.3892/or.2018.6644 (opens in a new tab)

  43. 43.

    Cheong H. (2015 ). Integrating autophagy and metabolism in cancer. Arch. Pharm. Res. 38 358–371.

    Not in our library10.1007/s12272-015-0562-2 (opens in a new tab)

  44. 44.

    Choi J. Gyamfi J. Jang H. Koo J. S. (2018a ). The role of tumor-associated macrophage in breast cancer biology. Histol. Histopathol. 33 133–145.

    Not in our library10.14670/hh-11-916 (opens in a new tab)

  45. 45.

    Choi J. Kim E. S. Koo J. S. (2018b ). Expression of Pentose Phosphate Pathway-Related Proteins in Breast Cancer. Dis. Markers 2018:9369358.

    Not in our library10.1155/2018/9369358 (opens in a new tab)

  46. 46.

    Choi J. Jung W. H. Koo J. S. (2013 ). Metabolism-related proteins are differentially expressed according to the molecular subtype of invasive breast cancer defined by surrogate immunohistochemistry. Pathobiology 80 41–52.

    Not in our library10.1159/000339513 (opens in a new tab)

  47. 47.

    Christofk H. R. Vander Heiden M. G. Harris M. H. Ramanathan A. Gerszten R. E. Wei R. (2008 ). The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452 230–233.

    Not in our library10.1038/nature06734 (opens in a new tab)

  48. 48.

    Colegio O. R. Chu N. Q. Szabo A. L. Chu T. Rhebergen A. M. Jairam V. (2014 ). Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513 559–563.

    Not in our library10.1038/nature13490 (opens in a new tab)

  49. 49.

    Conover C. A. Lee P. D. Kanaley J. A. Clarkson J. T. Jensen M. D. (1992 ). Insulin regulation of insulin-like growth factor binding protein-1 in obese and nonobese humans. J. Clin. Endocrinol. Metab. 74 1355–1360.

    Not in our library10.1210/jcem.74.6.1375600 (opens in a new tab)

  50. 50.

    Corbet C. Feron O. (2017 ). Cancer cell metabolism and mitochondria: nutrient plasticity for TCA cycle fueling. Biochim. Biophys. Acta Rev. Cancer 1868 7–15.

    Not in our library10.1016/j.bbcan.2017.01.002 (opens in a new tab)

  51. 51.

    Coyle T. Levante S. Shetler M. Winfield J. (1994 ). In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines. J. Neurooncol. 19 25–35.

    Not in our library10.1007/bf01051046 (opens in a new tab)

  52. 52.

    Cybulski N. Hall M. N. (2009 ). TOR complex 2: a signaling pathway of its own. Trends Biochem. Sci. 34 620–627.

    Not in our library10.1016/j.tibs.2009.09.004 (opens in a new tab)

  53. 53.

    De Blasio A. Di Fiore R. Pratelli G. Drago-Ferrante R. Saliba C. Baldacchino S. (2020 ). A loop involving NRF2, miR-29b-1-5p and AKT, regulates cell fate of MDA-MB-231 triple-negative breast cancer cells. J. Cell Physiol. 235 629–637.

    Not in our library10.1002/jcp.29062 (opens in a new tab)

  54. 54.

    Debeb B. G. Lacerda L. Larson R. Wolfe A. R. Krishnamurthy S. Reuben J. M. (2016 ). Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. Oncotarget 7 28329–28339.

    Not in our library10.18632/oncotarget.8631 (opens in a new tab)

  55. 55.

    Denko N. C. (2008 ). Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer 8 705–713.

    Not in our library10.1038/nrc2468 (opens in a new tab)

  56. 56.

    DeSantis C. E. Bray F. Ferlay J. Lortet-Tieulent J. Anderson B. O. Jemal A. (2015 ). International Variation in Female Breast Cancer Incidence and Mortality Rates. Cancer Epidemiol. Biomarkers Prev. 24 1495–1506.

    Not in our library10.1158/1055-9965.epi-15-0535 (opens in a new tab)

  57. 57.

    Doherty J. R. Cleveland J. L. (2013 ). Targeting lactate metabolism for cancer therapeutics. J. Clin. Invest. 123 3685–3692.

    Not in our library10.1172/jci69741 (opens in a new tab)

  58. 58.

    Dong C. Yuan T. Wu Y. Wang Y. Fan T. W. Miriyala S. (2013 ). Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell 23 316–331.

    Not in our library10.1016/j.ccr.2013.01.022 (opens in a new tab)

  59. 59.

    Dong T. Kang X. Liu Z. Zhao S. Ma W. Xuan Q. (2016 ). Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer. Tumour Biol. 37 8159–8168.

    Not in our library10.1007/s13277-015-4729-8 (opens in a new tab)

  60. 60.

    Dong T. Liu Z. Xuan Q. Wang Z. Ma W. Zhang Q. (2017 ). Tumor LDH-A expression and serum LDH status are two metabolic predictors for triple negative breast cancer brain metastasis. Sci. Rep. 7:6069.

    Not in our library10.1038/s41598-017-06378-7 (opens in a new tab)

  61. 61.

    Douard V. Ferraris R. P. (2008 ). Regulation of the fructose transporter GLUT5 in health and disease. Am. J. Physiol. Endocrinol. Metab. 295 E227–E237.

    Not in our library10.1152/ajpendo.90245.2008 (opens in a new tab)

  62. 62.

    Doyen J. Trastour C. Ettore F. Peyrottes I. Toussant N. Gal J. (2014 ). Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome. Biochem. Biophys. Res. Commun. 451 54–61.

    Not in our library10.1016/j.bbrc.2014.07.050 (opens in a new tab)

  63. 63.

    Dupuy F. Tabariès S. Andrzejewski S. Dong Z. Blagih J. Annis M. G. (2015 ). PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer. Cell Metab. 22 577–589.

    Not in our library10.1016/j.cmet.2015.08.007 (opens in a new tab)

  64. 64.

    Düvel K. Yecies J. L. Menon S. Raman P. Lipovsky A. I. Souza A. L. (2010 ). Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39 171–183.

    Not in our library10.1016/j.molcel.2010.06.022 (opens in a new tab)

  65. 65.

    Engelman J. A. Luo J. Cantley L. C. (2006 ). The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7 606–619.

    Not in our library10.1038/nrg1879 (opens in a new tab)

  66. 66.

    Farabegoli F. Vettraino M. Manerba M. Fiume L. Roberti M. Di Stefano G. (2012 ). Galloflavin, a new lactate dehydrogenase inhibitor, induces the death of human breast cancer cells with different glycolytic attitude by affecting distinct signaling pathways. Eur. J. Pharm. Sci. 47 729–738.

    Not in our library10.1016/j.ejps.2012.08.012 (opens in a new tab)

  67. 67.
    The reverse Warburg effect is likely to be an Achilles' heel of cancer that can be exploited for cancer therapy · 2017
    No notice
  68. 68.

    Furuta E. Okuda H. Kobayashi A. Watabe K. (2010 ). Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim. Biophys. Acta 1805 141–152.

    Not in our library10.1016/j.bbcan.2010.01.005 (opens in a new tab)

  69. 69.
    PSAT1 is regulated by ATF4 and enhances cell proliferation via the GSK3β/β-catenin/cyclin D1 signaling pathway in ER-negative breast cancer · 2017
    No notice
  70. 70.

    García-Castillo V. López-Urrutia E. Villanueva-Sánchez O. Ávila-Rodríguez M. Zentella-Dehesa A. Cortés-González C. (2017 ). Targeting Metabolic Remodeling in Triple Negative Breast Cancer in a Murine Model. J. Cancer 8 178–189.

    Not in our library10.7150/jca.16387 (opens in a new tab)

  71. 71.

    García-Martínez J. M. Alessi D. R. (2008 ). mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J. 416 375–385.

    Not in our library10.1042/bj20081668 (opens in a new tab)

  72. 72.

    Garrido P. Morán J. Alonso A. González S. González C. (2013 ). 17β-estradiol activates glucose uptake via GLUT4 translocation and PI3K/Akt signaling pathway in MCF-7 cells. Endocrinology 154 1979–1989.

    Not in our library10.1210/en.2012-1558 (opens in a new tab)

  73. 73.

    Gayosso V. Montano L. F. López-Marure R. (2006 ). DHEA-induced antiproliferative effect in MCF-7 cells is androgen- and estrogen receptor-independent. Cancer J. 12 160–165.

    Not in our library

  74. 74.

    Geeraerts S. L. Heylen E. De Keersmaecker K. Kampen K. R. (2021a ). The ins and outs of serine and glycine metabolism in cancer. Nat. Metab. 3 131–141.

    Not in our library10.1038/s42255-020-00329-9 (opens in a new tab)

  75. 75.

    Geeraerts S. L. Kampen K. R. Rinaldi G. Gupta P. Planque M. Louros N. (2021b ). Repurposing the Antidepressant Sertraline as SHMT Inhibitor to Suppress Serine/Glycine Synthesis-Addicted Breast Tumor Growth. Mol. Cancer Ther. 20 50–63.

    Not in our library10.1158/1535-7163.mct-20-0480 (opens in a new tab)

  76. 76.

    Ghanavat M. Shahrouzian M. Deris Zayeri Z. Banihashemi S. Kazemi S. M. Saki N. (2021 ). Digging deeper through glucose metabolism and its regulators in cancer and metastasis. Life Sci. 264:118603.

    Not in our library10.1016/j.lfs.2020.118603 (opens in a new tab)

  77. 77.

    Giatromanolaki A. Koukourakis M. I. Simopoulos C. Polychronidis A. Gatter K. C. Harris A. L. (2004 ). c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent. Clin. Cancer Res. 10 7972–7977.

    Not in our library10.1158/1078-0432.ccr-04-1068 (opens in a new tab)

  78. 78.

    Gilbert N. E. O’Reilly J. E. Chang C. J. Lin Y. C. Brueggemeier R. W. (1995 ). Antiproliferative activity of gossypol and gossypolone on human breast cancer cells. Life Sci. 57 61–67.

    Not in our library10.1016/0024-3205(95)00243-y (opens in a new tab)

  79. 79.

    Godoy A. Ulloa V. Rodríguez F. Reinicke K. Yañez A. J. García Mde L. (2006 ). Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J. Cell Physiol. 207 614–627.

    Not in our library10.1002/jcp.20606 (opens in a new tab)

  80. 80.

    Gomez L. S. Zancan P. Marcondes M. C. Ramos-Santos L. Meyer-Fernandes J. R. Sola-Penna M. (2013 ). Resveratrol decreases breast cancer cell viability and glucose metabolism by inhibiting 6-phosphofructo-1-kinase. Biochimie 95 1336–1343.

    Not in our library10.1016/j.biochi.2013.02.013 (opens in a new tab)

  81. 81.

    Gorres B. K. Bomhoff G. L. Morris J. K. Geiger P. C. (2011 ). In vivo stimulation of oestrogen receptor α increases insulin-stimulated skeletal muscle glucose uptake. J. Physiol. 589 2041–2054.

    Not in our library10.1113/jphysiol.2010.199018 (opens in a new tab)

  82. 82.

    Grinde M. T. Moestue S. A. Borgan E. Risa Ø Engebraaten O. Gribbestad I. S. (2011 ). 13C high-resolution-magic angle spinning MRS reveals differences in glucose metabolism between two breast cancer xenograft models with different gene expression patterns. NMR Biomed. 24 1243–1252.

    Not in our library10.1002/nbm.1683 (opens in a new tab)

  83. 83.

    Groheux D. Cochet A. Humbert O. Alberini J. L. Hindié E. Mankoff D. (2016 ). 18F-FDG PET/CT for Staging and Restaging of Breast Cancer. J. Nucl. Med. 57 17s–26s.

    Not in our library10.2967/jnumed.115.157859 (opens in a new tab)

  84. 84.

    Grover-McKay M. Walsh S. A. Seftor E. A. Thomas P. A. Hendrix M. J. (1998 ). Role for glucose transporter 1 protein in human breast cancer. Pathol. Oncol. Res. 4 115–120.

    Not in our library10.1007/bf02904704 (opens in a new tab)

  85. 85.

    Guedes M. Araújo J. R. Correia-Branco A. Gregório I. Martel F. Keating E. (2016 ). Modulation of the uptake of critical nutrients by breast cancer cells by lactate: impact on cell survival, proliferation and migration. Exp. Cell Res. 341 111–122.

    Not in our library10.1016/j.yexcr.2016.01.008 (opens in a new tab)

  86. 86.

    Gunter M. J. Xie X. Xue X. Kabat G. C. Rohan T. E. Wassertheil-Smoller S. (2015 ). Breast cancer risk in metabolically healthy but overweight postmenopausal women. Cancer Res. 75 270–274.

    Not in our library10.1158/0008-5472.can-14-2317 (opens in a new tab)

  87. 87.

    Halestrap A. P. Connern C. P. Griffiths E. J. Kerr P. M. (1997 ). Cyclosporin A binding to mitochondrial cyclophilin inhibits the permeability transition pore and protects hearts from ischaemia/reperfusion injury. Mol. Cell Biochem. 174 167–172.

    Not in our library10.1007/978-1-4615-6111-8_25 (opens in a new tab)

  88. 88.

    Han J. Zhang L. Guo H. Wysham W. Z. Roque D. R. Willson A. K. (2015 ). Glucose promotes cell proliferation, glucose uptake and invasion in endometrial cancer cells via AMPK/mTOR/S6 and MAPK signaling. Gynecol. Oncol. 138 668–675.

    Not in our library10.1016/j.ygyno.2015.06.036 (opens in a new tab)

  89. 89.

    Hara K. Maruki Y. Long X. Yoshino K. Oshiro N. Hidayat S. (2002 ). Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110 177–189.

    Not in our library10.1016/s0092-8674(02)00833-4 (opens in a new tab)

  90. 90.

    Hare S. H. Harvey A. J. (2017 ). mTOR function and therapeutic targeting in breast cancer. Am. J. Cancer Res. 7 383–404.

    Not in our library

  91. 91.

    Harmon A. W. Patel Y. M. (2004 ). Naringenin inhibits glucose uptake in MCF-7 breast cancer cells: a mechanism for impaired cellular proliferation. Breast Cancer Res. Treat 85 103–110.

    Not in our library10.1023/b:brea.0000025397.56192.e2 (opens in a new tab)

  92. 92.

    Hibdon E. S. Razumilava N. Keeley T. M. Wong G. Solanki S. Shah Y. M. (2019 ). Notch and mTOR Signaling Pathways Promote Human Gastric Cancer Cell Proliferation. Neoplasia 21 702–712.

    Not in our library10.1016/j.neo.2019.05.002 (opens in a new tab)

  93. 93.
    Characterization of macrophage - cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer · 2015
    No notice
  94. 94.
    Structure, function and regulation of mammalian glucose transporters of the SLC2 family · 2020
    No notice
  95. 95.

    Hsieh A. L. Walton Z. E. Altman B. J. Stine Z. E. Dang C. V. (2015 ). MYC and metabolism on the path to cancer. Semin. Cell Dev. Biol. 43 11–21.

    Not in our library10.1016/j.semcdb.2015.08.003 (opens in a new tab)

  96. 96.

    Huang X. Li X. Xie X. Ye F. Chen B. Song C. (2016 ). High expressions of LDHA and AMPK as prognostic biomarkers for breast cancer. Breast 30 39–46.

    Not in our library10.1016/j.breast.2016.08.014 (opens in a new tab)

  97. 97.

    Hui S. Ghergurovich J. M. Morscher R. J. Jang C. Teng X. Lu W. (2017 ). Glucose feeds the TCA cycle via circulating lactate. Nature 551 115–118.

    Not in our library10.1038/nature24057 (opens in a new tab)

  98. 98.

    Hussein Y. R. Bandyopadhyay S. Semaan A. Ahmed Q. Albashiti B. Jazaerly T. (2011 ). Glut-1 Expression Correlates with Basal-like Breast Cancer. Transl. Oncol. 4 321–327.

    Not in our library10.1593/tlo.11256 (opens in a new tab)

  99. 99.

    Ikenoue T. Inoki K. Yang Q. Zhou X. Guan K. L. (2008 ). Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J. 27 1919–1931.

    Not in our library10.1038/emboj.2008.119 (opens in a new tab)

  100. 100.

    Irey E. A. Lassiter C. M. Brady N. J. Chuntova P. Wang Y. Knutson T. P. (2019 ). JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors. Proc. Natl. Acad. Sci. U. S. A. 116 12442–12451.

    Not in our library10.1073/pnas.1816410116 (opens in a new tab)

  101. 101.

    Jia D. Lu M. Jung K. H. Park J. H. Yu L. Onuchic J. N. (2019 ). Elucidating cancer metabolic plasticity by coupling gene regulation with metabolic pathways. Proc. Natl. Acad. Sci. U. S. A. 116 3909–3918.

    Not in our library10.1073/pnas.1816391116 (opens in a new tab)

  102. 102.
    Elucidating the Metabolic Plasticity of Cancer: Mitochondrial Reprogramming and Hybrid Metabolic States · 2018
    No notice
  103. 103.

    Jia L. Huang S. Yin X. Zan Y. Guo Y. Han L. (2018 ). Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction. Life Sci. 208 123–130.

    Not in our library10.1016/j.lfs.2018.07.027 (opens in a new tab)

  104. 104.

    Jiang K. He B. Lai L. Chen Q. Liu Y. Guo Q. (2012 ). Cyclosporine A inhibits breast cancer cell growth by downregulating the expression of pyruvate kinase subtype M2. Int. J. Mol. Med. 30 302–308.

    Not in our library10.3892/ijmm.2012.989 (opens in a new tab)

  105. 105.

    Jiang S. Zhang L. F. Zhang H. W. Hu S. Lu M. H. Liang S. (2012 ). A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. EMBO J. 31 1985–1998.

    Not in our library10.1038/emboj.2012.45 (opens in a new tab)

  106. 106.

    Jin M. S. Lee H. Park I. A. Chung Y. R. Im S. A. Lee K. H. (2016 ). Overexpression of HIF1α and CAXI predicts poor outcome in early-stage triple negative breast cancer. Virchows Arch. 469 183–190.

    Not in our library10.1007/s00428-016-1953-6 (opens in a new tab)

  107. 107.

    Johnson J. M. Cotzia P. Fratamico R. Mikkilineni L. Chen J. Colombo D. (2017 ). MCT1 in Invasive Ductal Carcinoma: monocarboxylate Metabolism and Aggressive Breast Cancer. Front. Cell Dev. Biol. 5:27.

    Not in our library10.3389/fcell.2017.00027 (opens in a new tab)

  108. 108.

    Jung K. H. Lee J. H. Thien Quach C. H. Paik J. Y. Oh H. Park J. W. (2013 ). Resveratrol suppresses cancer cell glucose uptake by targeting reactive oxygen species-mediated hypoxia-inducible factor-1α activation. J. Nucl. Med. 54 2161–2167.

    Not in our library10.2967/jnumed.112.115436 (opens in a new tab)

  109. 109.

    Kabat G. C. Kim M. Caan B. J. Chlebowski R. T. Gunter M. J. Ho G. Y. (2009 ). Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int. J. Cancer 125 2704–2710.

    Not in our library10.1002/ijc.24609 (opens in a new tab)

  110. 110.

    Kang S. S. Chun Y. K. Hur M. H. Lee H. K. Kim Y. J. Hong S. R. (2002 ). Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma. Jpn J. Cancer Res. 93 1123–1128.

    Not in our library10.1111/j.1349-7006.2002.tb01214.x (opens in a new tab)

  111. 111.

    Katzenellenbogen B. S. Norman M. J. (1990 ). Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen. Endocrinology 126 891–898.

    Not in our library10.1210/endo-126-2-891 (opens in a new tab)

  112. 112.

    Kawauchi K. Araki K. Tobiume K. Tanaka N. (2008 ). p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat. Cell Biol. 10 611–618.

    Not in our library10.1038/ncb1724 (opens in a new tab)

  113. 113.

    Kim H. M. Jung W. H. Koo J. S. (2014 ). Site-specific metabolic phenotypes in metastatic breast cancer. J. Transl. Med. 12:354.

    Not in our library10.1186/s12967-014-0354-3 (opens in a new tab)

  114. 114.

    Kim S. K. Jung W. H. Koo J. S. (2014 ). Differential expression of enzymes associated with serine/glycine metabolism in different breast cancer subtypes. PLoS One 9:e101004.

    Not in our library10.1371/journal.pone.0101004 (opens in a new tab)

  115. 115.

    Kim Y. H. Jung W. H. Koo J. S. (2014 ). Expression of metabolism-related proteins in invasive lobular carcinoma: comparison to invasive ductal carcinoma. Tumour Biol. 35 10381–10393.

    Not in our library10.1007/s13277-014-2345-7 (opens in a new tab)

  116. 116.

    Kim S. Kim D. H. Jung W. H. Koo J. S. (2013 ). Metabolic phenotypes in triple-negative breast cancer. Tumour Biol. 34 1699–1712.

    Not in our library10.1007/s13277-013-0707-1 (opens in a new tab)

  117. 117.

    Koboldt D. C. Fulton R. S. McLellan M. D. Schmidt H. Kalicki-Veizer J. McMichael J. F. (2012 ). Comprehensive molecular portraits of human breast tumours. Nature 490 61–70.

    Not in our library10.1038/nature11412 (opens in a new tab)

  118. 118.

    Kruger N. J. von Schaewen A. (2003 ). The oxidative pentose phosphate pathway: structure and organisation. Curr. Opin. Plant Biol. 6 236–246.

    Not in our library10.1016/s1369-5266(03)00039-6 (opens in a new tab)

  119. 119.
    Expression of GLUT1 and GLUT3 Glucose Transporters in Endometrial and Breast Cancers · 2012
    No notice
  120. 120.

    Kumar P. Aggarwal R. (2016 ). An overview of triple-negative breast cancer. Arch. Gynecol. Obstet. 293 247–269.

    Not in our library10.1007/s00404-015-3859-y (opens in a new tab)

  121. 121.

    Labrie F. Luu-The V. Labrie C. Simard J. (2001 ). DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Front. Neuroendocrinol. 22 185–212.

    Not in our library10.1006/frne.2001.0216 (opens in a new tab)

  122. 122.

    Labuschagne C. F. van den Broek N. J. Mackay G. M. Vousden K. H. Maddocks O. D. (2014 ). Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells. Cell Rep. 7 1248–1258.

    Not in our library10.1016/j.celrep.2014.04.045 (opens in a new tab)

  123. 123.

    Lai X. Li Q. Wu F. Lin J. Chen J. Zheng H. (2020 ). Epithelial-Mesenchymal Transition and Metabolic Switching in Cancer: lessons From Somatic Cell Reprogramming. Front. Cell Dev. Biol. 8:760.

    Not in our library10.3389/fcell.2020.00760 (opens in a new tab)

  124. 124.
    Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities · 2017
    No notice
  125. 125.

    Lawlor D. A. Smith G. D. Ebrahim S. (2004 ). Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women’s Heart and Health Study. Cancer Causes Control 15 267–275.

    Not in our library10.1023/b:caco.0000024225.14618.a8 (opens in a new tab)

  126. 126.

    LeBleu V. S. O’Connell J. T. Gonzalez Herrera K. N. Wikman H. Pantel K. Haigis M. C. (2014 ). PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat. Cell Biol. 16 992–1003.

    Not in our library10.1038/ncb3039 (opens in a new tab)

  127. 127.

    Lee J. H. Liu R. Li J. Wang Y. Tan L. Li X. J. (2018 ). EGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation. Mol. Cell 70 197–210.e7.

    Not in our library10.1016/j.molcel.2018.03.018 (opens in a new tab)

  128. 128.

    Lee M. Yoon J. H. (2015 ). Metabolic interplay between glycolysis and mitochondrial oxidation: the reverse Warburg effect and its therapeutic implication. World J. Biol. Chem. 6 148–161.

    Not in our library10.4331/wjbc.v6.i3.148 (opens in a new tab)

  129. 129.

    Lee Y. R. Park J. Yu H. N. Kim J. S. Youn H. J. Jung S. H. (2005 ). Up-regulation of PI3K/Akt signaling by 17beta-estradiol through activation of estrogen receptor-alpha, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells. Biochem. Biophys. Res. Commun. 336 1221–1226.

    Not in our library10.1016/j.bbrc.2005.08.256 (opens in a new tab)

  130. 130.

    Lehmann B. D. Bauer J. A. Chen X. Sanders M. E. Chakravarthy A. B. Shyr Y. (2011 ). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121 2750–2767.

    Not in our library10.1172/jci45014 (opens in a new tab)

  131. 131.

    Leino R. L. Gerhart D. Z. van Bueren A. M. McCall A. L. Drewes L. R. (1997 ). Ultrastructural localization of GLUT 1 and GLUT 3 glucose transporters in rat brain. J. Neurosci. Res. 49 617–626.

    Not in our library10.1002/(sici)1097-4547(19970901)49:5<617::aid-jnr12<3.0.co;2-s (opens in a new tab)

  132. 132.

    Levine A. J. Puzio-Kuter A. M. (2010 ). The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330 1340–1344.

    Not in our library10.1126/science.1193494 (opens in a new tab)

  133. 133.

    Li L. J. Li G. W. Xie Y. (2019 ). [Regulatory effects of glabridin and quercetin on energy metabolism of breast cancer cells]. Zhongguo Zhong Yao Za Zhi 44 3786–3791.

    Not in our library10.19540/j.cnki.cjcmm.20190505.401 (opens in a new tab)

  134. 134.

    Li X. B. Gu J. D. Zhou Q. H. (2015 ). Review of aerobic glycolysis and its key enzymes - new targets for lung cancer therapy. Thorac Cancer 6 17–24.

    Not in our library10.1111/1759-7714.12148 (opens in a new tab)

  135. 135.

    Li Z. Wu Q. Sun S. Wu J. Li J. Zhang Y. (2018 ). Monocarboxylate transporters in breast cancer and adipose tissue are novel biomarkers and potential therapeutic targets. Biochem. Biophys. Res. Commun. 501 962–967.

    Not in our library10.1016/j.bbrc.2018.05.091 (opens in a new tab)

  136. 136.

    Lin A. Li C. Xing Z. Hu Q. Liang K. Han L. (2016 ). The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer. Nat. Cell Biol. 18 213–224.

    Not in our library10.1038/ncb3295 (opens in a new tab)

  137. 137.

    Lin Y. Lv F. Liu F. Guo X. Fan Y. Gu F. (2015 ). High Expression of Pyruvate Kinase M2 is Associated with Chemosensitivity to Epirubicin and 5-Fluorouracil in Breast Cancer. J. Cancer 6 1130–1139.

    Not in our library10.7150/jca.12719 (opens in a new tab)

  138. 138.

    Liu Y. Cao Y. Zhang W. Bergmeier S. Qian Y. Akbar H. (2012 ). A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol. Cancer Ther. 11 1672–1682.

    Not in our library10.1158/1535-7163.mct-12-0131 (opens in a new tab)

  139. 139.

    Liu Z. Sun Y. Hong H. Zhao S. Zou X. Ma R. (2015 ). 3-bromopyruvate enhanced daunorubicin-induced cytotoxicity involved in monocarboxylate transporter 1 in breast cancer cells. Am. J. Cancer Res. 5 2673–2685.

    Not in our library

  140. 140.

    Liu Z. Zhang Y. Y. Zhang Q. W. Zhao S. R. Wu C. Z. Cheng X. (2014 ). 3-Bromopyruvate induces apoptosis in breast cancer cells by downregulating Mcl-1 through the PI3K/Akt signaling pathway. Anticancer Drugs 25 447–455.

    Not in our library10.1097/cad.0000000000000081 (opens in a new tab)

  141. 141.

    Locasale J. W. (2013 ). Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat. Rev. Cancer 13 572–583.

    Not in our library10.1038/nrc3557 (opens in a new tab)

  142. 142.

    Locasale J. W. Grassian A. R. Melman T. Lyssiotis C. A. Mattaini K. R. Bass A. J. (2011 ). Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat. Genet. 43 869–874.

    Not in our library10.1038/ng.890 (opens in a new tab)

  143. 143.

    López-Lázaro M. (2008 ). The warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen? Anticancer Agents Med. Chem. 8 305–312.

    Not in our library10.2174/187152008783961932 (opens in a new tab)

  144. 144.

    López-Marure R. Contreras P. G. Dillon J. S. (2011 ). Effects of dehydroepiandrosterone on proliferation, migration, and death of breast cancer cells. Eur. J. Pharmacol. 660 268–274.

    Not in our library10.1016/j.ejphar.2011.03.040 (opens in a new tab)

  145. 145.

    Losada-Echeberría M. Herranz-López M. Micol V. Barrajón-Catalán E. (2017 ). Polyphenols as Promising Drugs against Main Breast Cancer Signatures. Antioxidants (Basel) 6:88.

    Not in our library10.3390/antiox6040088 (opens in a new tab)

  146. 146.

    Luo M. Shang L. Brooks M. D. Jiagge E. Zhu Y. Buschhaus J. M. (2018 ). Targeting Breast Cancer Stem Cell State Equilibrium through Modulation of Redox Signaling. Cell Metab. 28 69–86.e6.

    Not in our library10.1016/j.cmet.2018.06.006 (opens in a new tab)

  147. 147.

    Ma C. Zu X. Liu K. Bode A. M. Dong Z. Liu Z. (2019 ). Knockdown of Pyruvate Kinase M Inhibits Cell Growth and Migration by Reducing NF-kB Activity in Triple-Negative Breast Cancer Cells. Mol. Cells 42 628–636.

    Not in our library10.14348/molcells.2019.0038 (opens in a new tab)

  148. 148.

    MacQueen G. Born L. Steiner M. (2001 ). The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev. 7 1–24.

    Not in our library10.1111/j.1527-3458.2001.tb00188.x (opens in a new tab)

  149. 149.

    Mantovani A. Sozzani S. Locati M. Allavena P. Sica A. (2002 ). Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23 549–555.

    Not in our library10.1016/s1471-4906(02)02302-5 (opens in a new tab)

  150. 150.

    Mao Y. Keller E. T. Garfield D. H. Shen K. Wang J. (2013 ). Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev. 32 303–315.

    Not in our library10.1007/s10555-012-9415-3 (opens in a new tab)

  151. 151.

    Marsin A. S. Bertrand L. Rider M. H. Deprez J. Beauloye C. Vincent M. F. (2000 ). Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr. Biol. 10 1247–1255.

    Not in our library10.1016/s0960-9822(00)00742-9 (opens in a new tab)

  152. 152.

    Martínez-Reyes I. Chandel N. S. (2017 ). Waste Not, Want Not: lactate Oxidation Fuels the TCA Cycle. Cell Metab. 26 803–804.

    Not in our library10.1016/j.cmet.2017.11.005 (opens in a new tab)

  153. 153.

    McCleland M. L. Adler A. S. Shang Y. Hunsaker T. Truong T. Peterson D. (2012 ). An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer. Cancer Res. 72 5812–5823.

    Not in our library10.1158/0008-5472.can-12-1098 (opens in a new tab)

  154. 154.

    McVie-Wylie A. J. Lamson D. R. Chen Y. T. (2001 ). Molecular cloning of a novel member of the GLUT family of transporters, SLC2a10 (GLUT10), localized on chromosome 20q13.1: a candidate gene for NIDDM susceptibility. Genomics 72 113–117.

    Not in our library10.1006/geno.2000.6457 (opens in a new tab)

  155. 155.

    Messeha S. S. Zarmouh N. O. Mendonca P. Alwagdani H. Cotton C. Soliman K. F. A. (2019 ). Effects of gossypol on apoptosis-related gene expression in racially distinct triple-negative breast cancer cells. Oncol. Rep. 42 467–478.

    Not in our library10.3892/or.2019.7179 (opens in a new tab)

  156. 156.

    Mishra J. Davani A. J. Natarajan G. K. Kwok W. M. Stowe D. F. Camara A. K. S. (2019 ). Cyclosporin A Increases Mitochondrial Buffering of Calcium: an Additional Mechanism in Delaying Mitochondrial Permeability Transition Pore Opening. Cells 8:1052.

    Not in our library10.3390/cells8091052 (opens in a new tab)

  157. 157.

    Mittal S. Brown N. J. Holen I. (2018 ). The breast tumor microenvironment: role in cancer development, progression and response to therapy. Expert. Rev. Mol. Diagn. 18 227–243.

    Not in our library10.1080/14737159.2018.1439382 (opens in a new tab)

  158. 158.

    Mocanu M. M. Nagy P. Szöllõsi J. (2015 ). Chemoprevention of Breast Cancer by Dietary Polyphenols. Molecules 20 22578–22620.

    Not in our library10.3390/molecules201219864 (opens in a new tab)

  159. 159.
    Metabolic Heterogeneity of Cancer Cells: An Interplay between HIF-1, GLUTs, and AMPK · 2020
    No notice
  160. 160.

    Moreira L. Araújo I. Costa T. Correia-Branco A. Faria A. Martel F. (2013 ). Quercetin and epigallocatechin gallate inhibit glucose uptake and metabolism by breast cancer cells by an estrogen receptor-independent mechanism. Exp. Cell Res. 319 1784–1795.

    Not in our library10.1016/j.yexcr.2013.05.001 (opens in a new tab)

  161. 161.

    Mu X. Shi W. Xu Y. Xu C. Zhao T. Geng B. (2018 ). Tumor-derived lactate induces M2 macrophage polarization via the activation of the ERK/STAT3 signaling pathway in breast cancer. Cell Cycle 17 428–438.

    Not in our library10.1080/15384101.2018.1444305 (opens in a new tab)

  162. 162.

    Mueckler M. Thorens B. (2013 ). The SLC2 (GLUT) family of membrane transporters. Mol. Aspects Med. 34 121–138.

    Not in our library10.1016/j.mam.2012.07.001 (opens in a new tab)

  163. 163.

    Mullarky E. Lucki N. C. Beheshti Zavareh R. Anglin J. L. Gomes A. P. Nicolay B. N. (2016 ). Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers. Proc. Natl. Acad. Sci. U. S. A. 113 1778–1783.

    Not in our library10.1073/pnas.1521548113 (opens in a new tab)

  164. 164.

    Niu W. Huang C. Nawaz Z. Levy M. Somwar R. Li D. (2003 ). Maturation of the regulation of GLUT4 activity by p38 MAPK during L6 cell myogenesis. J. Biol. Chem. 278 17953–17962.

    Not in our library10.1074/jbc.m211136200 (opens in a new tab)

  165. 165.

    Noh E. M. Lee Y. R. Chay K. O. Chung E. Y. Jung S. H. Kim J. S. (2011 ). Estrogen receptor α induces down-regulation of PTEN through PI3-kinase activation in breast cancer cells. Mol. Med Rep. 4 215–219.

    Not in our library10.3892/mmr.2011.412 (opens in a new tab)

  166. 166.

    Noh S. Kim D. H. Jung W. H. Koo J. S. (2014 ). Expression levels of serine/glycine metabolism-related proteins in triple negative breast cancer tissues. Tumour Biol. 35 4457–4468.

    Not in our library10.1007/s13277-013-1588-z (opens in a new tab)

  167. 167.

    Novellasdemunt L. Tato I. Navarro-Sabate A. Ruiz-Meana M. Méndez-Lucas A. Perales J. C. (2013 ). Akt-dependent activation of the heart 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB2) isoenzyme by amino acids. J. Biol. Chem. 288 10640–10651.

    Not in our library10.1074/jbc.m113.455998 (opens in a new tab)

  168. 168.

    Oh S. Kim H. Nam K. Shin I. (2017 ). Glut1 promotes cell proliferation, migration and invasion by regulating epidermal growth factor receptor and integrin signaling in triple-negative breast cancer cells. BMB Rep. 50 132–137.

    Not in our library10.5483/bmbrep.2017.50.3.189 (opens in a new tab)

  169. 169.

    Okar D. A. Manzano A. Navarro-Sabatè A. Riera L. Bartrons R. Lange A. J. (2001 ). PFK-2/FBPase-2: maker and breaker of the essential biofactor fructose-2,6-bisphosphate. Trends Biochem. Sci. 26 30–35.

    Not in our library10.1016/s0968-0004(00)01699-6 (opens in a new tab)

  170. 170.

    O’Neal J. Clem A. Reynolds L. Dougherty S. Imbert-Fernandez Y. Telang S. (2016 ). Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer. Breast Cancer Res. Treat. 160 29–40.

    Not in our library10.1007/s10549-016-3968-8 (opens in a new tab)

  171. 171.

    Pacold M. E. Brimacombe K. R. Chan S. H. Rohde J. M. Lewis C. A. Swier L. J. (2016 ). A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate. Nat. Chem. Biol. 12 452–458.

    Not in our library10.1038/nchembio.2070 (opens in a new tab)

  172. 172.

    Palaskas N. Larson S. M. Schultz N. Komisopoulou E. Wong J. Rohle D. (2011 ). 18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res. 71 5164–5174.

    Not in our library10.1158/0008-5472.can-10-4633 (opens in a new tab)

  173. 173.

    Pan Y. Zheng Q. Ni W. Wei Z. Yu S. Jia Q. (2019 ). Breaking Glucose Transporter 1/Pyruvate Kinase M2 Glycolytic Loop Is Required for Cantharidin Inhibition of Metastasis in Highly Metastatic Breast Cancer. Front. Pharmacol. 10:590.

    Not in our library10.3389/fphar.2019.00590 (opens in a new tab)

  174. 174.

    Park J. H. Vithayathil S. Kumar S. Sung P. L. Dobrolecki L. E. Putluri V. (2016 ). Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep. 14 2154–2165.

    Not in our library10.1016/j.celrep.2016.02.004 (opens in a new tab)

  175. 175.

    Pasanen I. Lehtonen S. Sormunen R. Skarp S. Lehtilahti E. Pietilä M. (2016 ). Breast cancer carcinoma-associated fibroblasts differ from breast fibroblasts in immunological and extracellular matrix regulating pathways. Exp. Cell Res. 344 53–66.

    Not in our library10.1016/j.yexcr.2016.04.016 (opens in a new tab)

  176. 176.

    Patra K. C. Hay N. (2014 ). The pentose phosphate pathway and cancer. Trends Biochem. Sci. 39 347–354.

    Not in our library10.1016/j.tibs.2014.06.005 (opens in a new tab)

  177. 177.

    Pavlides S. Whitaker-Menezes D. Castello-Cros R. Flomenberg N. Witkiewicz A. K. Frank P. G. (2009 ). The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 8 3984–4001.

    Not in our library10.4161/cc.8.23.10238 (opens in a new tab)

  178. 178.

    Paydary K. Seraj S. M. Zadeh M. Z. Emamzadehfard S. Shamchi S. P. Gholami S. (2019 ). The Evolving Role of FDG-PET/CT in the Diagnosis, Staging, and Treatment of Breast Cancer. Mol. Imaging Biol. 21 1–10.

    Not in our library10.1007/s11307-018-1181-3 (opens in a new tab)

  179. 179.
    Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential · 2014
    No notice
  180. 180.

    Peng F. Li Q. Sun J. Y. Luo Y. Chen M. Bao Y. (2018 ). PFKFB3 is involved in breast cancer proliferation, migration, invasion and angiogenesis. Int. J. Oncol. 52 945–954.

    Not in our library10.3892/ijo.2018.4257 (opens in a new tab)

  181. 181.

    Pinheiro C. Albergaria A. Paredes J. Sousa B. Dufloth R. Vieira D. (2010 ). Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. Histopathology 56 860–867.

    Not in our library10.1111/j.1365-2559.2010.03560.x (opens in a new tab)

  182. 182.

    Pinheiro C. Sousa B. Albergaria A. Paredes J. Dufloth R. Vieira D. (2011 ). GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. Histol. Histopathol. 26 1279–1286.

    Not in our library10.14670/hh-26.1279 (opens in a new tab)

  183. 183.

    Possemato R. Marks K. M. Shaul Y. D. Pacold M. E. Kim D. Birsoy K. (2011 ). Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476 346–350.

    Not in our library10.1038/nature10350 (opens in a new tab)

  184. 184.

    Preuss J. Richardson A. D. Pinkerton A. Hedrick M. Sergienko E. Rahlfs S. (2013 ). Identification and characterization of novel human glucose-6-phosphate dehydrogenase inhibitors. J. Biomol. Screen 18 286–297.

    Not in our library10.1177/1087057112462131 (opens in a new tab)

  185. 185.

    Pu H. Zhang Q. Zhao C. Shi L. Wang Y. Wang J. (2015 ). Overexpression of G6PD is associated with high risks of recurrent metastasis and poor progression-free survival in primary breast carcinoma. World J. Surg. Oncol. 13:323.

    Not in our library10.1186/s12957-015-0733-0 (opens in a new tab)

  186. 186.

    Ralser M. Wamelink M. M. Struys E. A. Joppich C. Krobitsch S. Jakobs C. (2008 ). A catabolic block does not sufficiently explain how 2-deoxy-D-glucose inhibits cell growth. Proc. Natl. Acad. Sci. U. S. A. 105 17807–17811.

    Not in our library10.1073/pnas.0803090105 (opens in a new tab)

  187. 187.

    Ramos-Martinez J. I. (2017 ). The regulation of the pentose phosphate pathway: remember Krebs. Arch. Biochem. Biophys. 614 50–52.

    Not in our library10.1016/j.abb.2016.12.012 (opens in a new tab)

  188. 188.

    Rastogi S. Banerjee S. Chellappan S. Simon G. R. (2007 ). Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines. Cancer Lett. 257 244–251.

    Not in our library10.1016/j.canlet.2007.07.021 (opens in a new tab)

  189. 189.

    Ravazoula P. Batistatou A. Aletra C. Ladopoulos J. Kourounis G. Tzigounis B. (2003 ). Immunohistochemical expression of glucose transporter Glut1 and cyclin D1 in breast carcinomas with negative lymph nodes. Eur. J. Gynaecol. Oncol. 24 544–546.

    Not in our library

  190. 190.
    The proteomic analysis of breast cell line exosomes reveals disease patterns and potential biomarkers · 2020
    No notice
  191. 191.

    Rivenzon-Segal D. Margalit R. Degani H. (2002 ). Glycolysis as a metabolic marker in orthotopic breast cancer, monitored by in vivo (13)C MRS. Am. J. Physiol. Endocrinol. Metab. 283 E623–E630.

    Not in our library10.1152/ajpendo.00050.2002 (opens in a new tab)

  192. 192.

    Robey I. F. Lien A. D. Welsh S. J. Baggett B. K. Gillies R. J. (2005 ). Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia 7 324–330.

    Not in our library10.1593/neo.04430 (opens in a new tab)

  193. 193.

    Rogers S. Docherty S. E. Slavin J. L. Henderson M. A. Best J. D. (2003 ). Differential expression of GLUT12 in breast cancer and normal breast tissue. Cancer Lett. 193 225–233.

    Not in our library10.1016/s0304-3835(03)00010-7 (opens in a new tab)

  194. 194.

    Rogers S. Macheda M. L. Docherty S. E. Carty M. D. Henderson M. A. Soeller W. C. (2002 ). Identification of a novel glucose transporter-like protein-GLUT-12. Am. J. Physiol. Endocrinol. Metab. 282 E733–E738.

    Not in our library10.1152/ajpendo.2002.282.3.e733 (opens in a new tab)

  195. 195.

    Ronda A. C. Buitrago C. Boland R. (2010a ). Role of estrogen receptors, PKC and Src in ERK2 and p38 MAPK signaling triggered by 17β-estradiol in skeletal muscle cells. J. Steroid Biochem. Mol. Biol. 122 287–294.

    Not in our library10.1016/j.jsbmb.2010.05.002 (opens in a new tab)

  196. 196.

    Ronda A. C. Vasconsuelo A. Boland R. (2010b ). Extracellular-regulated kinase and p38 mitogen-activated protein kinases are involved in the antiapoptotic action of 17beta-estradiol in skeletal muscle cells. J. Endocrinol. 206 235–246.

    Not in our library10.1677/joe-09-0429 (opens in a new tab)

  197. 197.

    Rossouw J. E. Anderson G. L. Prentice R. L. LaCroix A. Z. Kooperberg C. Stefanick M. L. (2002 ). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288 321–333.

    Not in our library10.1001/jama.288.3.321 (opens in a new tab)

  198. 198.

    Salazar G. (2018 ). NADPH Oxidases and Mitochondria in Vascular Senescence. Int. J. Mol. Sci. 19:1327.

    Not in our library10.3390/ijms19051327 (opens in a new tab)

  199. 199.

    Samanta D. Park Y. Andrabi S. A. Shelton L. M. Gilkes D. M. Semenza G. L. (2016 ). PHGDH Expression Is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung Metastasis. Cancer Res. 76 4430–4442.

    Not in our library10.1158/0008-5472.can-16-0530 (opens in a new tab)

  200. 200.

    Samih N. Hovsepian S. Aouani A. Lombardo D. Fayet G. (2000 ). Glut-1 translocation in FRTL-5 thyroid cells: role of phosphatidylinositol 3-kinase and N-glycosylation. Endocrinology 141 4146–4155.

    Not in our library10.1210/endo.141.11.7793 (opens in a new tab)

  201. 201.

    Santos J. M. Hussain F. (2020 ). Higher Glucose Enhances Breast Cancer Cell Aggressiveness. Nutr. Cancer 72 734–746.

    Not in our library10.1080/01635581.2019.1654527 (opens in a new tab)

  202. 202.

    Santos J. M. Khan Z. S. Munir M. T. Tarafdar K. Rahman S. M. Hussain F. (2018 ). Vitamin D(3) decreases glycolysis and invasiveness, and increases cellular stiffness in breast cancer cells. J. Nutr. Biochem. 53 111–120.

    Not in our library10.1016/j.jnutbio.2017.10.013 (opens in a new tab)

  203. 203.

    Sato-Tadano A. Suzuki T. Amari M. Takagi K. Miki Y. Tamaki K. (2013 ). Hexokinase II in breast carcinoma: a potent prognostic factor associated with hypoxia-inducible factor-1α and Ki-67. Cancer Sci. 104 1380–1388.

    Not in our library10.1111/cas.12238 (opens in a new tab)

  204. 204.

    Schieber M. S. Chandel N. S. (2013 ). ROS links glucose metabolism to breast cancer stem cell and EMT phenotype. Cancer Cell 23 265–267.

    Not in our library10.1016/j.ccr.2013.02.021 (opens in a new tab)

  205. 205.

    Semenza G. L. (2017 ). Hypoxia-inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype. EMBO J. 36 252–259.

    Not in our library10.15252/embj.201695204 (opens in a new tab)

  206. 206.

    Semenza G. L. Roth P. H. Fang H. M. Wang G. L. (1994 ). Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 269 23757–23763.

    Not in our library10.1016/s0021-9258(17)31580-6 (opens in a new tab)

  207. 207.

    Shen L. O’Shea J. M. Kaadige M. R. Cunha S. Wilde B. R. Cohen A. L. (2015 ). Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. Proc. Natl. Acad. Sci. U. S. A. 112 5425–5430.

    Not in our library10.1073/pnas.1501555112 (opens in a new tab)

  208. 208.

    Shi Y. Zhang Y. Ran F. Liu J. Lin J. Hao X. (2020 ). Let-7a-5p inhibits triple-negative breast tumor growth and metastasis through GLUT12-mediated warburg effect. Cancer Lett. 495 53–65.

    Not in our library10.1016/j.canlet.2020.09.012 (opens in a new tab)

  209. 209.

    Simões R. V. Serganova I. S. Kruchevsky N. Leftin A. Shestov A. A. Thaler H. T. (2015 ). Metabolic plasticity of metastatic breast cancer cells: adaptation to changes in the microenvironment. Neoplasia 17 671–684.

    Not in our library10.1016/j.neo.2015.08.005 (opens in a new tab)

  210. 210.

    Simoncini T. Hafezi-Moghadam A. Brazil D. P. Ley K. Chin W. W. Liao J. K. (2000 ). Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407 538–541.

    Not in our library10.1038/35035131 (opens in a new tab)

  211. 211.

    Sitter B. Bathen T. F. Singstad T. E. Fjøsne H. E. Lundgren S. Halgunset J. (2010 ). Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed. 23 424–431.

    Not in our library10.1002/nbm.1478 (opens in a new tab)

  212. 212.

    Sonveaux P. Végran F. Schroeder T. Wergin M. C. Verrax J. Rabbani Z. N. (2008 ). Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 118 3930–3942.

    Not in our library10.1172/jci36843 (opens in a new tab)

  213. 213.

    Soysal S. D. Tzankov A. Muenst S. E. (2015 ). Role of the Tumor Microenvironment in Breast Cancer. Pathobiology 82 142–152.

    Not in our library10.1159/000430499 (opens in a new tab)

  214. 214.
    The return of metabolism: biochemistry and physiology of the pentose phosphate pathway · 2014
    No notice
  215. 215.

    Tseng C. W. Kuo W. H. Chan S. H. Chan H. L. Chang K. J. Wang L. H. (2018 ). Transketolase Regulates the Metabolic Switch to Control Breast Cancer Cell Metastasis via the α-Ketoglutarate Signaling Pathway. Cancer Res. 78 2799–2812.

    Not in our library10.1158/0008-5472.can-17-2906 (opens in a new tab)

  216. 216.

    Ueno T. Utsumi J. Toi M. Shimizu K. (2015 ). Characteristic Gene Expression Profiles of Human Fibroblasts and Breast Cancer Cells in a Newly Developed Bilateral Coculture System. Biomed. Res. Int. 2015:960840.

    Not in our library10.1155/2015/960840 (opens in a new tab)

  217. 217.

    Unterlass J. E. Baslé A. Blackburn T. J. Tucker J. Cano C. Noble M. E. M. (2018 ). Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer. Oncotarget 9 13139–13153.

    Not in our library10.18632/oncotarget.11487 (opens in a new tab)

  218. 218.

    Vargas E. Podder V. Carrillo Sepulveda M. A. (2021 ). Physiology, Glucose Transporter Type 4. Treasure Island: StatPearls Publishing.

    Not in our library

  219. 219.

    Vivanco I. Sawyers C. L. (2002 ). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2 489–501.

    Not in our library10.1038/nrc839 (opens in a new tab)

  220. 220.

    Vousden K. H. Ryan K. M. (2009 ). p53 and metabolism. Nat. Rev. Cancer 9 691–700.

    Not in our library10.1038/nrc2715 (opens in a new tab)

  221. 221.

    Wang J. Duan Z. Nugent Z. Zou J. X. Borowsky A. D. Zhang Y. (2016 ). Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes. Cancer Lett. 378 69–79.

    Not in our library10.1016/j.canlet.2016.05.004 (opens in a new tab)

  222. 222.

    Wang Q. Liberti M. V. Liu P. Deng X. Liu Y. Locasale J. W. (2017 ). Rational Design of Selective Allosteric Inhibitors of PHGDH and Serine Synthesis with Anti-tumor Activity. Cell Chem. Biol. 24 55–65.

    Not in our library10.1016/j.chembiol.2016.11.013 (opens in a new tab)

  223. 223.
    Metabolic reprogramming in triple-negative breast cancer · 2020
    No notice
  224. 224.

    Warburg O. (1956 ). On the origin of cancer cells. Science 123 309–314.

    Not in our library10.1126/science.123.3191.309 (opens in a new tab)

  225. 225.

    Wei R. Mao L. Xu P. Zheng X. Hackman R. M. Mackenzie G. G. (2018 ). Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models. Food Funct. 9 5682–5696.

    Not in our library10.1039/c8fo01397g (opens in a new tab)

  226. 226.

    Wellberg E. A. Johnson S. Finlay-Schultz J. Lewis A. S. Terrell K. L. Sartorius C. A. (2016 ). The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis. Breast Cancer Res. 18:131.

    Not in our library10.1186/s13058-016-0795-0 (opens in a new tab)

  227. 227.

    Whitaker-Menezes D. Martinez-Outschoorn U. E. Lin Z. Ertel A. Flomenberg N. Witkiewicz A. K. (2011 ). Evidence for a stromal-epithelial “lactate shuttle” in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle 10 1772–1783.

    Not in our library10.4161/cc.10.11.15659 (opens in a new tab)

  228. 228.

    Wilde L. Roche M. Domingo-Vidal M. Tanson K. Philp N. Curry J. (2017 ). Metabolic coupling and the Reverse Warburg Effect in cancer: implications for novel biomarker and anticancer agent development. Semin. Oncol. 44 198–203.

    Not in our library10.1053/j.seminoncol.2017.10.004 (opens in a new tab)

  229. 229.
    The role of polyphenols in modern nutrition · 2017
    No notice
  230. 230.

    Witkiewicz A. K. Whitaker-Menezes D. Dasgupta A. Philp N. J. Lin Z. Gandara R. (2012 ). Using the “reverse Warburg effect” to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle 11 1108–1117.

    Not in our library10.4161/cc.11.6.19530 (opens in a new tab)

  231. 231.
    Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells · 2015
    No notice
  232. 232.

    Wright E. M. (2013 ). Glucose transport families SLC5 and SLC50. Mol Aspects Med. 34 183–196.

    Not in our library10.1016/j.mam.2012.11.002 (opens in a new tab)

  233. 233.

    Wu Q. Heidenreich D. Zhou S. Ackloo S. Krämer A. Nakka K. (2019a ). A chemical toolbox for the study of bromodomains and epigenetic signaling. Nat. Commun. 10:1915.

    Not in our library10.1038/s41467-019-09672-2 (opens in a new tab)

  234. 234.
    Cancer-associated adipocytes: key players in breast cancer progression · 2019
    No notice
  235. 235.

    Wuest M. Hamann I. Bouvet V. Glubrecht D. Marshall A. Trayner B. (2018 ). Molecular Imaging of GLUT1 and GLUT5 in Breast Cancer: a Multitracer Positron Emission Tomography Imaging Study in Mice. Mol. Pharmacol. 93 79–89.

    Not in our library10.1124/mol.117.110007 (opens in a new tab)

  236. 236.

    Xi H. Barredo J. C. Merchan J. R. Lampidis T. J. (2013 ). Endoplasmic reticulum stress induced by 2-deoxyglucose but not glucose starvation activates AMPK through CaMKKβ leading to autophagy. Biochem. Pharmacol. 85 1463–1477.

    Not in our library10.1016/j.bcp.2013.02.037 (opens in a new tab)

  237. 237.

    Xi H. Kurtoglu M. Liu H. Wangpaichitr M. You M. Liu X. (2011 ). 2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion. Cancer Chemother. Pharmacol. 67 899–910.

    Not in our library10.1007/s00280-010-1391-0 (opens in a new tab)

  238. 238.
    A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models · 2015
    No notice
  239. 239.

    Yang L. Li J. Li Y. Zhou Y. Wang Z. Zhang D. (2021 ). Diclofenac impairs the proliferation and glucose metabolism of triple-negative breast cancer cells by targeting the c-Myc pathway. Exp. Ther. Med. 21:584.

    Not in our library10.3892/etm.2021.10016 (opens in a new tab)

  240. 240.
    PIM2-mediated phosphorylation of hexokinase 2 is critical for tumor growth and paclitaxel resistance in breast cancer · 2018
    Corrected
  241. 241.

    Yang X. Peng X. Huang J. (2018 ). Inhibiting 6-phosphogluconate dehydrogenase selectively targets breast cancer through AMPK activation. Clin. Transl. Oncol. 20 1145–1152.

    Not in our library10.1007/s12094-018-1833-4 (opens in a new tab)

  242. 242.

    Yang Y. Wolfram J. Boom K. Fang X. Shen H. Ferrari M. (2013 ). Hesperetin impairs glucose uptake and inhibits proliferation of breast cancer cells. Cell Biochem. Funct. 31 374–379.

    Not in our library10.1002/cbf.2905 (opens in a new tab)

  243. 243.

    Yang Z. J. Chee C. E. Huang S. Sinicrope F. A. (2011 ). The role of autophagy in cancer: therapeutic implications. Mol. Cancer Ther. 10 1533–1541.

    Not in our library10.1158/1535-7163.mct-11-0047 (opens in a new tab)

  244. 244.

    Ye W. Chang H. L. Wang L. S. Huang Y. W. Shu S. Sugimoto Y. (2010 ). Induction of apoptosis by (-)-gossypol-enriched cottonseed oil in human breast cancer cells. Int. J. Mol. Med. 26 113–119.

    Not in our library

  245. 245.

    Yeh W. L. Lin C. J. Fu W. M. (2008 ). Enhancement of glucose transporter expression of brain endothelial cells by vascular endothelial growth factor derived from glioma exposed to hypoxia. Mol. Pharmacol. 73 170–177.

    Not in our library10.1124/mol.107.038851 (opens in a new tab)

  246. 246.

    Yin K. (2015 ). Positive correlation between expression level of mitochondrial serine hydroxymethyltransferase and breast cancer grade. Onco. Targets Ther. 8 1069–1074.

    Not in our library10.2147/ott.s82433 (opens in a new tab)

  247. 247.

    Younes M. Brown R. W. Mody D. R. Fernandez L. Laucirica R. (1995 ). GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res. 15 2895–2898.

    Not in our library

  248. 248.
    Modulation of Glucose Transporter 1 (GLUT1) Expression Levels Alters Mouse Mammary Tumor Cell Growth In Vitro and In Vivo · 2011
    No notice
  249. 249.

    Yousefi S. Darvishi P. Yousefi Z. Pourfathollah A. A. (2020 ). Effect of methyl jasmonate and 3-bromopyruvate combination therapy on mice bearing the 4 T1 breast cancer cell line. J. Bioenerg. Biomembr. 52 103–111.

    Not in our library10.1007/s10863-019-09811-w (opens in a new tab)

  250. 250.

    Zamora-León S. P. Golde D. W. Concha I. I. Rivas C. I. Delgado-López F. Baselga J. (1996 ). Expression of the fructose transporter GLUT5 in human breast cancer. Proc. Natl. Acad. Sci. U. S. A. 93 1847–1852.

    Not in our library10.1073/pnas.93.5.1847 (opens in a new tab)

  251. 251.

    Zhao F. Ming J. Zhou Y. Fan L. (2016 ). Inhibition of Glut1 by WZB117 sensitizes radioresistant breast cancer cells to irradiation. Cancer Chemother. Pharmacol. 77 963–972.

    Not in our library10.1007/s00280-016-3007-9 (opens in a new tab)

  252. 252.

    Zhao Y. Liu H. Liu Z. Ding Y. Ledoux S. P. Wilson G. L. (2011 ). Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res. 71 4585–4597.

    Not in our library10.1158/0008-5472.can-11-0127 (opens in a new tab)

  253. 253.

    Zhong H. De Marzo A. M. Laughner E. Lim M. Hilton D. A. Zagzag D. (1999 ). Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59 5830–5835.

    Not in our library

  254. 254.
    Warburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes Taxol-resistant cancer cells to Taxol · 2010
    No notice
  255. 255.

    Zhu S. Wei L. Lin G. Tong Y. Zhang J. Jiang X. (2020 ). Metabolic Alterations Induced by Kudingcha Lead to Cancer Cell Apoptosis and Metastasis Inhibition. Nutr. Cancer 72 696–707.

    Not in our library10.1080/01635581.2019.1645865 (opens in a new tab)

Cited by papers we hold 1

Questions about this paper

We email you if it is retracted, withdrawn, corrected or flagged.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.